<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1612246436
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        STRATTERA 10MG CAPSULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ATOMOXETINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        224.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LILLY DEL CARIBE, INC." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LILLY DEL CARIBE, INC.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 718]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ARAC HEALTHCARE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Lilly,S.A
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06BA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What it is used for</strong></p><p>Strattera contains atomoxetine and is used to treat attention-deficit and hyperactivity disorder (ADHD). It is used</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in children over six&nbsp;years of age</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in young people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in adults</p><p>It is used only as a part of the total treatment of the disease which also requires treatments which do not involve medicines, such as counselling and behavioural therapy.</p><p>It is not for use as a treatment for ADHD in children under 6&nbsp;years of age as it is not known if the drug works or is safe in these people.</p><p>In adults, Strattera is used to treat ADHD when the symptoms are very troublesome and affect your work or social life and when you have had symptoms of the disease as a child.</p><p>&nbsp;</p><p><strong>How it works</strong></p><p>Strattera increases the amount of noradrenaline in the brain. This is a chemical that is produced naturally, and increases attention and decreases impulsiveness and hyperactivity in patients with ADHD. This medicine has been prescribed to help control the symptoms of ADHD. This medicine is not a stimulant and is therefore not addictive.</p><p>It may take a few&nbsp;weeks after you start the medicine for your symptoms to fully improve.</p><p>&nbsp;</p><p><strong>About ADHD</strong></p><p>Children and young people with ADHD find it:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hard to sit still and</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hard to concentrate.</p><p>It is not their fault that they cannot do these things. Many children and young people struggle to do these things. However, with ADHD this can cause problems with everyday life. Children and young people with ADHD may have difficulty learning and doing homework. They find it hard to behave well at home, at school or in other places. ADHD does not affect the intelligence of a child or young person.</p><p>&nbsp;</p><p>Adults with ADHD find it difficult to do all the things that children find difficult; however this may mean they have problems with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; work</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; relationships</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low self esteem</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; education</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do NOT take Strattera if you:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to atomoxetine or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; took a medicine known as a monoamine oxidase inhibitor (MAOI), for example phenelzine, in the last two&nbsp;weeks. An MAOI is sometimes used for depression and other mental-health problems; taking Strattera with an MAOI could cause serious side effects or be life-threatening. You also need to wait at least 14&nbsp;days after you stop taking Strattera before you take an MAOI</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an eye disease called narrow-angle glaucoma (increased pressure in your eye)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have serious problems with your heart which may be affected by an increase in heart rate and/or blood pressure, as this may be an effect of Strattera</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have serious problems with the blood vessels in your brain - such as a stroke, swelling and weakening of part of a blood vessel (aneurysm) or narrow or blocked blood vessels</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a tumour of your adrenal gland (phaeochromocytoma)</p><p>Do not take Strattera if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before you take Strattera. This is because Strattera can make these problems worse.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Both adult and children should be aware of the following warnings and precautions. Talk to your doctor or pharmacist before taking Strattera if you have:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thoughts about killing yourself or trying to kill yourself.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with your heart (including heart defects) or an increased heartbeat. Strattera can increase your heart rate (pulse). Sudden death has been reported in patients with heart defects.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure. Strattera can increase blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure. Strattera can cause dizziness or fainting in people with low blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with sudden changes in your blood pressure or your heart rate.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiovascular disease or past medical history of stroke.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver problems. You may need a lower dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; psychotic symptoms including hallucinations (hearing voices or seeing things which are not there), believing things that are not true or being suspicious.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mania (feeling elated or over-excited, which causes unusual behaviour) and agitation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aggressive feelings.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unfriendly and angry (hostility) feelings.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a history of epilepsy or have had seizures for any other reason. Strattera might lead to an increase in seizure frequency.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; different moods than usual (mood swings) or feel very unhappy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hard-to-control, repeated twitching of any parts of the body or you repeat sounds and words.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if any of the above applies to you before starting treatment. This is because Strattera can make these problems worse. Your doctor will want to monitor how the medicine affects you.</p><p>&nbsp;</p><p><strong>Checks that your doctor will make before you start to take Strattera</strong></p><p>These checks are to decide if Strattera is the correct medicine for you.</p><p>Your doctor will<strong> </strong>measure your</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood pressure and your heart rate (pulse) before and during the time you take Strattera</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your height and weight if you are a child or teenager during the time you take Strattera</p><p>Your doctor will talk to you about:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any other medicines you are taking</p><p>-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;whether there is any family history of sudden unexplained death</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any other medical problems (such as heart problems) you or your family may have</p><p>It is important that you provide as much information as you can. This will help your doctor decide if Strattera is the correct medicine for you. Your doctor may decide that other medical tests are needed before you start taking this medicine.</p><p>&nbsp;</p><p><strong>Other medicines and Strattera</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might&nbsp; take any other medicines. This includes non-prescription medicines. Your doctor will decide if you can take Strattera with your other medicines and in some cases your doctor may need to adjust your dose or increase your dose much more slowly.</p><p>Do not take Strattera with medicines called MAOIs (monoamine oxidase inhibitors) used for depression. See section 2 &ldquo;Do not take Strattera&rdquo;.</p><p>If you are taking other medicines, Strattera may affect how well they work or may cause side effects. If you are taking any of the following medicines, check with your doctor or pharmacist before taking Strattera:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that increase blood pressure or are used to control blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines such as antidepressants, for example imipramine, venlafaxine, mirtazapine, fluoxetine and paroxetine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some cough and cold remedies which contain medicines that can affect blood pressure. It is important to check with your pharmacist when you get any of these products</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines used to treat mental health conditions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;medicines that are known to increase the risk of seizures</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;some medicines that cause Strattera to stay in the body for longer than normal (such as quinidine and terbinafine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;salbutamol (a medicine to treat asthma) when taken by mouth or injected may make you feel as if your heart is racing, but this will not make your asthma worse</p><p>The medicines below may lead to an increased risk of an abnormal rhythm of the heart when taken with Strattera:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to control the rhythm of the heart</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines which change the concentration of salts in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for malaria prevention and treatment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antibiotic medicines (such as erythromycin and moxifloxacin)</p><p>If you are not sure about whether any medicines you are taking are included in the list above, ask your doctor or pharmacist before taking Strattera.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>It is not known if this medicine can affect an unborn baby or pass into breast milk.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine should not be used during pregnancy, unless your doctor has advised you to do so.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should either avoid taking this medicine if you are breastfeeding or discontinue breastfeeding.</p><p>If you are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pregnant or breast feeding,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thinking that you may be pregnant or are planning to have a baby,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; planning to breastfeed your baby</p><p>ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You may feel tired, sleepy or dizzy after taking Strattera. You should be careful if you are driving a car or operating machinery until you know how Strattera affects you. If you feel tired, sleepy or dizzy you should not drive or operate machinery.</p><p>&nbsp;</p><p><strong>Important information about the content of the capsules</strong></p><p>Do not open Strattera capsules because the contents of the capsule can irritate the eye. If the contents of the capsules come into contact with the eye, the affected eye should be flushed immediately with water, and medical advice obtained. Hands and any other part of the body that may have come into contact with the capsule contents should also be washed as soon as possible.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. This is usually one or two times a day (morning and late afternoon or early evening)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children should not take this medicine without the help from an adult.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking Strattera once a day and experience sleepiness or feel sick, your doctor may change your treatment schedule to twice a day</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsules should be swallowed whole, either with or without food</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsules should not be opened and the contents inside the capsules should not be removed and taken in any other way</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking the medicine at the same time each day may help you remember to take it</p><p><strong>&nbsp;</strong></p><p><strong>How much to take</strong></p><p><strong>If you are a child or teenager (6&nbsp;years or older):</strong></p><p>Your doctor will tell you how much Strattera you should take and will calculate this according to your weight. He/she will normally start you on a lower dose before increasing the amount of Strattera you need to take according to your body weight.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Body weight up to 70&nbsp;kg: a starting total daily dose of 0.5&nbsp;mg per&nbsp;kg of body weight for a minimum of 7&nbsp;days. Your doctor may then decide to increase this to the usual maintenance dose of about 1.2&nbsp;mg per&nbsp;kg of body weight daily.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Body weight over 70&nbsp;kg: a starting total daily dose of 40&nbsp;mg for a minimum of 7&nbsp;days. Your doctor may then decide to increase this to the usual maintenance dose of 80&nbsp;mg daily. The maximum daily dose your doctor will prescribe is 100&nbsp;mg.</p><p><strong>&nbsp;</strong></p><p><strong>Adults</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Strattera should be started at a total daily dose of 40&nbsp;mg for a minimum of 7&nbsp;days. Your doctor may then decide to increase this to the usual maintenance dose of 80&nbsp;mg-100&nbsp;mg daily. The maximum daily dose your doctor will prescribe is 100&nbsp;mg.</p><p>If you have problems with your liver your doctor may prescribe a lower dose.</p><p>&nbsp;</p><p><strong>If you</strong><strong> take more Strattera than you should</strong> contact your doctor or the nearest hospital casualty department immediately and tell them how many capsules you have taken. The most commonly reported symptoms accompanying overdoses are gastrointestinal symptoms, sleepiness, dizziness, tremor, and abnormal behaviour.</p><p>&nbsp;</p><p><strong>If you forget to take Strattera</strong></p><p>If you miss a dose, you should take it as soon as possible, but you should not take more than your total daily dose in any 24-hour period. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Strattera</strong></p><p>If you stop taking Strattera there are usually no side effects but your ADHD symptoms may return. You should talk to your doctor first before you stop treatment.</p><p>&nbsp;</p><p><strong>Things your doctor will do when you are on treatment</strong></p><p><strong>Your doctor will do some tests</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; before you start - to make sure that Strattera is safe and will be of benefit.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after you start - they will be done at least every 6&nbsp;months, but possibly more often.</p><p>They will also be done when the dose is changed. These tests will include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; measuring height and weight in children and young people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; measuring blood pressure and heart rate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; checking whether you have any problems or if side effects have got worse while taking Strattera</p><p>&nbsp;</p><p><strong>Long-term treatment </strong></p><p>Strattera does not need to be taken for ever. If you take Strattera for more than a&nbsp;year, your doctor will review your treatment, to see if the medicine is still needed.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Although some people get side effects most people find that Strattera helps them. Your doctor will talk to you about these sides effects.</p><p>Some side effects could be serious<strong>. If you have any of the side effects below, see a doctor straight away.</strong></p><p><strong>Uncommon (</strong>may affect up to 1 in 100 people<strong>)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling or having a very fast heartbeat, abnormal rhythms of the heart</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thinking about or feeling like killing yourself</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling aggressive</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling unfriendly and angry (hostility)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mood swings or mood changes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious allergic reaction with symptoms of</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face and throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (small raised, itchy patches of skin)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; psychotic symptoms including hallucinations (hearing voices or seeing things which are not there), believing things that are not true or being suspicious<strong> </strong></p><p><strong>&nbsp;</strong></p><p><strong>Children and young adults aged under 18 have an increased risk of side</strong><strong> effects such as:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thinking about or feeling like killing yourself &nbsp;<strong>(</strong>may affect up to 1 in 100 people<strong>)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mood swings or mood changes <strong>(</strong>may affect up to 1 in 10 people<strong>)</strong></p><p>&nbsp;</p><p><strong>Adults have a reduced risk (</strong>may affect up to 1 in 1,000 people<strong>) of side effects such as:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; psychotic symptoms including hallucinations (hearing voices or seeing things which are not there), believing things that are not true or being suspicious</p><p><strong>&nbsp;</strong></p><p><strong>Rarely </strong>(may affect up to 1 in 1,000 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver injury<strong> </strong></p><p>&nbsp;</p><p><strong>You should stop taking Strattera and call your doctor immediately if you have any of the following:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dark urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellow skin or yellow eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tummy pain which is sore when you press it (tenderness) on the right side just below your ribs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a feeling of sickness (nausea) that is unexplained</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling that you are coming down with flu</p><p>&nbsp;</p><p><strong>Other side effects reported include the following. If they get serious, tell your doctor or pharmacist.</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td colspan="2"><p><strong>&nbsp;Very common</strong> side effects (may affect more than 1 in 10 people)</p></td></tr><tr><td style="vertical-align:top"><p><strong>CHILDREN and YOUNG PEOPLE over 6&nbsp;years</strong></p></td><td style="vertical-align:top"><p><strong>ADULTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the stomach</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite (not feeling hungry)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling or being sick</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased heart rate (pulse)</p><p>&nbsp;</p><p>These effects may disappear after a while in most patients.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite (not feeling hungry)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems getting to sleep, staying asleep and waking early</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased heart rate (pulse)</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:100%"><tbody><tr><td colspan="2"><p><strong>Common</strong> side effects (may affect up to 1 in 10 people)</p></td></tr><tr><td style="vertical-align:top"><p><strong>CHILDREN and YOUNG PEOPLE over 6&nbsp;years</strong></p></td><td style="vertical-align:top"><p><strong>ADULTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being irritable or agitated</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems sleeping including waking early</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sad or hopeless</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling anxious</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tics</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; large pupils (the dark centre of the eye)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upset stomach, indigestion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen, reddened and itchy skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling lazy (lethargy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p></td><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling agitated</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased interest in sex</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep disturbance</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sad or hopeless</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling anxious</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an abnormal taste or change in taste that will not go away</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling or numbness in the hands or feet</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness, drowsy, feeling tired</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach ache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wind (flatulence)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flush or flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling or having a very fast heartbeat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen, reddened and itchy skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems going to the toilet such as not be able to urinate, frequent or hesitant urinating, pain on urinating</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the prostate gland (prostatitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; groin pain in men</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; failure to obtain an erection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; retarded orgasm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty maintaining an erection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; menstrual cramps</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of strength or energy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling lazy (lethargy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling, irritable, jittery</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling thirsty</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:100%"><tbody><tr><td colspan="2"><p><strong>Uncommon</strong> side effects (may affect up to 1 in 100 people)</p></td></tr><tr><td style="vertical-align:top"><p><strong>CHILDREN and YOUNG PEOPLE over 6&nbsp;years</strong></p></td><td style="vertical-align:top"><p><strong>ADULTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; migraine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal skin sensation, such as burning, prickling, itching, or tingling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling or numbness in the hands or feet</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizure (fits)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling or having a very fast heartbeat (QT prolongation)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of strength or energy</p></td><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; restlessness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tics</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; migraine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart rhythm abnormal (QT prolongation)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling cold in fingers and toes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised red itchy rashes (hives)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an urge to urinate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal or absence of orgasm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular menstruation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ejaculation failure</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td colspan="2"><p><strong>Rare</strong> side effects (may affect up to 1 in 1,000 people)</p></td></tr><tr><td style="vertical-align:top"><p><strong>CHILDREN and YOUNG PEOPLE over 6&nbsp;years</strong></p></td><td style="vertical-align:top"><p><strong>ADULTS</strong></p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; poor blood circulation which makes toes and fingers numb and pale (Raynaud&rsquo;s disease)</p><p>-&nbsp;&nbsp; problems going to the toilet such as frequent or hesitant urinating, pain on urinating</p><p>-&nbsp;&nbsp; prolonged and painful erections</p><p>groin pain in males</p></td><td style="vertical-align:top"><p>-&nbsp;&nbsp; poor blood circulation which makes toes and fingers numb and pale (Raynaud&rsquo;s disease)</p><p>-&nbsp;&nbsp; prolonged and painful erections</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Effects on growth</strong></p><p>Some children experience reduced growth (weight and height) when they start taking Strattera. However, with long-term treatment, children recover to the weight and height for their age range.</p><p>Your doctor will watch your child&rsquo;s height and weight over time. If your child is not growing or gaining weight as expected, your doctor may change your child&rsquo;s dose or decide to stop Strattera temporarily.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in section 6. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date stated on the carton and blister after &lsquo;Exp&rsquo;. The expiry date refers to the last day of that&nbsp;month.</p><p>Store below 30&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is atomoxetine hydrochloride. Each hard capsule contains atomoxetine hydrochloride equivalent to 10&nbsp;mg, 18&nbsp;mg, 25&nbsp;mg, 40&nbsp;mg, 60&nbsp;mg of atomoxetine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are pregelatinised starch and dimeticone.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shells contain sodium laurilsulfate and gelatin. The capsule shell colourants are:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow iron oxide E172 (18&nbsp;mg, 60&nbsp;mg)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Titanium dioxide E171 (10&nbsp;mg, 18&nbsp;mg, 25&nbsp;mg, 40&nbsp;mg, 60&nbsp;mg))</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FD&amp;C blue 2 (indigo carmine) E132 (25&nbsp;mg, 40&nbsp;mg and 60&nbsp;mg)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Edible black ink (containing shellac and black iron oxide E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Capsule, hard, 10 mg (white, imprinted Lilly 3227/10 mg, approximately 15.5-16.1 mm length )
Capsule, hard, 18 mg (gold/white, imprinted Lilly 3238/18 mg, approximately 15.5-16.1 mm length)
Capsule, hard, 25 mg (blue/white, imprinted Lilly 3228/25 mg, approximately 15.5-16.1 mm length)
Capsule, hard, 40 mg (blue, imprinted Lilly 3229/40 mg, approximately 15.5-16.1 mm length)
Capsule, hard, 60 mg (blue/gold, imprinted Lilly 3239/60 mg, approximately 17.5-18.1 mm length)

Strattera capsules are available in packs of 7, 14, 28 or 56 capsules. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The marketing authorisation holder is: Eli Lilly S.A Avda. De la Industria, 30. 28108 Alcobendas. Madrid. Spain.</p><p>&nbsp;</p><p>The manufacturer is:</p><p>&nbsp;Lilly del Caribe, Inc. Puerto Rico Industrial Park. 12.6 KM 65<sup>th</sup> Infantry Road. Carolina, Puerto Rico 00985.</p><p>&nbsp;</p><p>The Primary and Secondary Packaging Site is:</p><p>Lilly S.A Avda. De la Industria, 30. 28108 Alcobendas. Madrid. Spain.</p><p>&nbsp;</p><p>For any information about this medicine, please contact the local Marketing Authorisation Holder:</p><p>Eli Lilly &amp; Company &ndash; Saudi Arabia</p><p>PO Box 92120</p><p>16th Floor, Building Number 3074,</p><p>Tower B, Olaya Towers</p><p>Prince Mohamed Ibn Abdulaziz Street</p><p>Olaya, Riyadh</p><p>Kingdom of Saudi Arabia</p><p>Direct Line:&nbsp; +966 11 461 7800, +966 11 4617850&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Fax: +966 11 217 9900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May/2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>فيم يستخدم</strong><strong> </strong><strong>ستراتيرا</strong></p><p dir="RTL">يحتوي ستراتيرا على الأتوموكزيتين و يستخدم لعلاج اضطراب تشتت الانتباه وفرط الحركة لدى:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال الأكثر من ست سنوات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;المراهقين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; و البالغين</p><p dir="RTL">و يستخدم كجزء فقط من برنامج علاجي شامل للمرض يتضمن أيضا بعض التدابير التي لا تعتمد على الأدوية كالإستشارة النفسية و العلاج النفسي السلوكي.</p><p dir="RTL">و لا ينصح باستعماله لعلاج اضطراب تشتت الانتباه وفرط الحركة لدى الأطفال أقل من 6 سنوات لعدم معرفة فعالية الدواء و سلامته لدى هؤلاء الأطفال.</p><p dir="RTL">يستخدم ستراتيرا لدى البالغين، لعلاج اضطراب تشتت الانتباه وفرط الحركة عندما تكون الأعراض مزعجة للغاية وتؤثر على عملك أو حياتك الاجتماعية وعندما تكون قد ظهرت عليك أعراض المرض عندما كنت طفلاً.</p><p dir="RTL"><strong>كيفية عمل ستراتيرا</strong></p><p dir="RTL">يساعد ستراتيرا على زيادة مادة النورأدرينالين في المخ؛ وهي مادة كيميائية تفرز بشكل طبيعي في المخ وتساعد على زيادة التنبه، كما تقلل من اندفاعية وفرط حركة مرضى اضطراب تشتت الانتباه وفرط الحركة. يوصف هذا الدواء للمساعدة على الحد من أعراض هذا الاضطراب. لا يعتبر هذا الدواء منبها و بالتالي لا ينتج عنه إدمان.</p><p dir="RTL">قد يستلزم الأمر مرور عدة أسابيع بعد البدء في تناول ستراتيرا لكي تلاحظ حدوث تحسن كامل للأعراض التي تعاني منها.</p><p dir="RTL"><strong>معلومات بخصوص اضطراب تشتت الانتباه وفرط الحركة</strong></p><p dir="RTL">يجد الأطفال المراهقون الذين يعانون من اضطراب تشتت الانتباه وفرط الحركة صعوبة في:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البقاء جالسين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; و التركيز.</p><p dir="RTL">وهذا ليس خطأهم إن كانو لا يستطيعون القيام بهذه الأمور، فالعديد من الأطفال و المراهقين غيرهم يعانون من مثل هذه الأمور. و لكن مع اضطراب تشتت الانتباه وفرط الحركة قد يسبب هذا مشاكل في الحياة اليومية. فالأطفال و المراهقون الذين يعانون من اضطراب تشتت الانتباه وفرط الحركة قد يجدون صعوبة في التعلم و القيام بالفروض المنزلية. كما يجدون صعوبة في التصرف بشكل جيد في المنزل أو المدرسة أو في أماكن أخرى. لا يؤثر على ذكاء الطفل أو المراهق.</p><p dir="RTL">يجد البالغون المصابون باضطراب تشتت الانتباه وفرط الحركة صعوبة في القيام بكل الأشياء التي يجدها الأطفال صعبة؛ ومع ذلك قد يعني هذا أن لديهم مشاكل في:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العمل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاقات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدني احترام الذات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعليم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول ستراتيرا:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط حساسية لمادة أتوموكزيتين أو أي من مكونات الدواء الأخرى) المذكورة في القسم6 ) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تناولت عقارا مثبطا للإنزيم المؤكسد لأحادي الأمين خلال الأسبوعين الماضيين؛ كعقار فينيلزين. فقد تستخدم مثبطات الإنزيم المؤكسد لأحادي الأمين، في بعض الأحيان، في علاج الاكتئاب وبعض مشاكل الصحة العقلية. وقد يتسبب تناول عقار ستراتيرا مع مثبطات الإنزيم المؤكسد لأحادي الأمين في حدوث بعض الآثار الجانبية الخطرة، مما قد يهدد حياة المريض. عليك أيضا أن تنتظر أربعة عشر يوما على الأقل بعد التوقف عن تناول ستراتيرا لكي تتمكن من تناول مثبطات الإنزيم المؤكسد لأحادي الأمين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من داء جلوكوما الزاوية الضيقة (أي ارتفاع الضغط داخل مقلة العين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل خطيرة في القلب والتي قد تتأثر بزيادة معدل ضربات القلب و/أو ضغط الدم، فقد يكون ذلك بسبب تأثير ستراتيرا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل خطيرة في أوعية الدماغ الدموية مثل السكتة الدماغية، وتورم وضعف جزء من الأوعية الدموية (تمدد الأوعية الدموية)، أو ضيق أو إنسداد الأوعية الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بورم في الغدة الكظرية (ورم القواتم)</p><p dir="RTL">لا تتناول ستراتيرا إذا كانت أحد الحالات المذكورة سابقا تنطبق عليك. إذا لم تكن متأكدا، تحدث إلى طبيبك أو الصيدلي قبل أخذ ستراتيرا .وذلك لكون ستراتيرا قد يجعل هذه المشاكل أكثر حدّة.</p><p dir="RTL"><strong>تحذيرات و احتياطات</strong></p><p dir="RTL"><strong>&nbsp;</strong>يجب على الأطفال و البالغين أن يكونوا على علم بالتحذيرات و الاحتياطات. قم باستشارة طبيبك المعالج أو الصيدلي قبل تناول ستراتيرا إذا كنت تعاني من:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار حول قتل نفسك أو محاولة قتل نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل قلبية (بما في ذلك العيوب الخلقية بالقلب) أو زيادة بمعدل ضربات القلب. يمكن أن يزيد ستراتيرا من معدل ضربات القلب (النبض). كما أنه قد تقرر حدوث بعض حالات الموت المفاجيء بين مرضى عيوب القلب الخلقية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم، حيث أن ستراتيرا قد يزيد من ارتفاع ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم، فقد يتسبب ستراتيرا في حدوث دوخة أو إغماءة لدى هؤلاء المرضى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تغييرات مفاجئة في ضغط الدم أو معدل نبضات القلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض قلبي وعائي أو قد عانيت من سكتة دماغية في السابق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالكبد، فقد تكون بحاجة إلى جرعات أقل من الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض ذهانية بما في ذلك الهلوسة (سماع الأصوات أو رؤية الأشياء التي لا وجود لها)، واعتقاد أشياء ليست صحيحة أو مشبوهة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهوس (الشعور بالكره أو فرط الإثارة، والذي يسبب سلوك غير عادي) و الهياج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشاعر العدوانية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشاعر غير الودية والغاضبة (العدوانية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاريخ &nbsp;من الصرع أو من التشنجات أيا كان المسبب، فقد يتسبب ستراتيرا في زيادة معدل حدوث التشنجات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرالمزاج على غير المعتاد (تقلب المزاج) أو الشعور الشديد بالحزن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات من الصعب السيطرة عليها، تكرار الوخز من أي جزء من الجسم أو كنت تكرر الأصوات والكلمات.</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي إذا كانت أحد الحالات المذكورة سابقا تنطبق عليك قبل أخذ ستراتيرا. وذلك لكون ستراتيرا قد يجعل هذه المشاكل أكثر حدّة. سوف یرغب طبیبك في مراقبة کیفیة تأثیر الدواء علیك.</p><p dir="RTL"><strong>بعض التدابير التي قد يتخذها طبيبك قبل أن تبدأ بأخذ</strong><strong> </strong><strong>ستراتير</strong></p><p dir="RTL">الغرض من هذه التدابير هو تحديد ما إذا كان سترتيرا هو الدواء الملائم لك.</p><p dir="RTL">سيقوم طبيبك بقياس:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم ومعدل ضربات القلب (النبض) قبل وأثناء الوقت الذي تتناول فيه ستراتيرا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طولك ووزنك إذا كنت طفلا أو مراهقا خلال الوقت الذي تأخذ فيه ستراتيرا</p><p dir="RTL">سيُحدّثك طبيبك بخصوص:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي أدوية أخرى تتناولها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما إذا كان هناك أي حالة الموت المفاجئ غير المبررة في تاريخ العائلة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي مشاكل طبیة أخرى (مثل مشاکل في القلب) قد تکون لدیك أنت أو عائلتك</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم أن تقدم أكبر قدر ممكن من المعلومات. هذا سيساعد طبيبك ليقرر ما إذا كان ستراتيرا هو الدواء الصحيح بالنسبة لك. قد يقرر طبيبك أن هناك حاجة لفحوص طبية أخرى قبل البدء في تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول عقاقير أخرى</strong><strong> </strong><strong>و ستراتيرا</strong></p><p dir="RTL">ينبغي عليك إبلاغ طبيبك أو الصيدلي بجميع العقاقير التي تقوم بتناولها أو قد تناولتها مؤخرا أو تنوي تناولها، بما في ذلك العقاقير التي تصرف بدون وصفة طبية. وسوف يقرر الطبيب مدى إمكانية تناولك لعقار ستراتيرا بجانب هذه العقاقير. وفي بعض الحالات قد يحتاج طبيبك إلى ضبط جرعتك أو زيادة جرعتك ببطء أكبر.</p><p dir="RTL">يجب تجنب استخدام ستراتيرا مع العقاقير المثبطة للإنزيم المؤكسد لأحادي الأمين الذي يستعمل لعلاج الإكتئاب. انظر القسم 2 &quot;لا تتناول ستراتيرا&quot;.</p><p dir="RTL">إذا كنت تتناول عقاقير أخرى، قد يؤثر ستراتيرا على نتائج العلاج بهذه العقاقير أو يسبب آثاراً جانبية.</p><p dir="RTL">&nbsp;إذا كنت تأخذ أيّاً من الأدوية التالية، استشر طبيبك أو الصيدلي قبل أخذ ستراتيرا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تسبب ارتفاع ضغط الدم أو تتحكم في ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تغير من مستوى النورأدرينالين بالدم، مثل مضادات الاكتئاب كعقار إيميبرامين وفينلافاكسين وميرتازابين &nbsp;و فلوكزيتين و باروكستين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض علاجات السعال والبرد التي تحتوي على الأدوية التي يمكن أن تؤثر على ضغط الدم. من المهم التحقق مع الصيدلي عند شراء أي من هذه الأدوية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تستخدم في علاج مشاكل الصحة العقلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تزيد من خطر التعرض للتشنجات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تسبب&nbsp; بقاء ستراتيرا في الجسم لفترة أطول من المعتاد (مثل الكينيدين و تربينافين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سالبوتامول (دواء لعلاج الربو) عندما يؤخذ عن طريق الفم أو الحقن قد يجعلك تشعر وكأن ضربات قلبك تتسارع، ولكن هذا لن يجعل الربو أسوأ</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأدوية أدناه قد تؤدي إلى زيادة خطر خفقان غير طبيعي للقلب عندما تؤخذ مع ستراتيرا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة للسيطرة على خفقان القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تغير تركيز الأملاح في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية الوقاية من الملاريا وعلاجها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المضادات الحيوية (مثل الاريثروميسين و موكسيفلوكساسين)</p><p dir="RTL">إذا لم تكن متأكدا مما إذا كانت أي أدوية تتناولها مدرجة في القائمة أعلاه، اسأل طبيبك أو الصيدلي قبل أخذ ستراتيرا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">من غير المعروف ما إذا كان هذا الدواء يمكن أن يؤثر على الجنين أو يمكن أن يمر في حليب الثدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم استخدام ستراتيرا أثناء الحمل إلا إذا وصف الطبيب خلاف ذلك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عليك أن تتجنبي تناول هذا الدواء أثناء فترة الرضاعة أو أوقفي الرضاعة</p><p dir="RTL">إذا كنت:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاملاً أو ترضعين،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ساورك شك أنك ممكن أن تكوني حاملا أو تخططين لذلك،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخططين لإرضاع طفلك</p><p dir="RTL">استشيري طبيبك قبل أخذ هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><strong> </strong></p><p dir="RTL">قد تشعر ببعض التعب أو الميل للنعاس أو التوعك بعد تناول ستراتيرا، لذا ينبغي عليك توخي الحذر عند قيادة السيارة أو تشغيل الآلات حتى تتعرف على مدى تأثير ستراتيرا عليك. ننصحك بتجنب القيادة واستخدام الآلات إذا شعرت بالتعب أو الميل للنعاس أو التوعك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة عن محتويات الكبسولة</strong></p><p dir="RTL">يجب عدم فتح كبسولات ستراتيرا حيث أن محتوياتها قد تتسبب في تهيج العينين. وفي حال تلامس محتويات الكبسولة للعين، قم فورا بغسل عينك بالماء ولا تتردد في طلب المشورة الطبية. كما ينبغي أيضا غسل اليدين و أي جزء آخر من الجسم الذي لامس محتويات الكبسولة فورا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم دائما بتناول هذا الدواء تماما كما وصفه لك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إن لم تكن متأكداً. وعادة ما يكون ذلك مرة أو مرتين يوميا (الصباح وبعد الظهر أو في وقت مبكر من المساء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجب أن يتناول الأطفال هذا الدواء من دون مساعدة بالغ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ ستراتيرا مرة واحدة في الوم و تعاني من الشعور بالنعاس والتوعك، من الممكن أن يغير طبيبك برنامج علاجك إلى مرتين باليوم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تناول الكبسولة كلها عن طريق الفم مع أو بدون الأكل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن لا تفتح الكبسولات، ولاينبغي أن تزيل مكونات الكبسولات و تأخذها بأية طريقة أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ننصح بتناول الدواء في نفس التوقيت من اليوم، حيث يساعد ذلك على تذكر موعد تناوله</p><p dir="RTL"><strong>كم يجب أن تأخذ</strong></p><p dir="RTL"><strong>إذا كنت طفلا أو مراهقا (أكثر من ست سنوات)</strong><strong>:</strong></p><p dir="RTL">سيحدد لك طبيبك جرعة ستراتيرا المناسبة لحالتك حسب وزن الجسم. وعادة ما يبدأ الطبيب في وصف الدواء بجرعات أقل، ثم يقوم بزيادتها تدريجيا حسب وزن جسمك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وزن الجسم حتى 70 كلجم: يجب البدء بجرعة يومية تبلغ 0.5 ملجم لكل كلجم من الجسم لمدة سبعة أيام على الأقل. قد يقرر طبيبك بعد ذلك زيادتها إلى الجرعة المعتادة، 1.2 ملجم&nbsp; في كل كلجم من الجسم يوميا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وزن الجسم أكثر من 70 كلجم : يجب البدء بجرعة 40 ملجم يوميا &nbsp;لمدة سبعة أيام على الأقل. قد يقرر طبيبك بعد ذلك زيادتها إلى الجرعة المعتادة، 80 ملجم يوميا. كما يجب ألا تتعدى الجرعة اليومية التي يصفها طبيبك 100 ملجم.</p><p dir="RTL"><strong>إذا كنت بالغاً</strong></p><p dir="RTL">ينبغي البدء في أخذ ستراتيرا بجرعة يومية إجمالية قدرها 40 ملجم لمدة لا تقل عن 7 أيام. قد يقرر طبيبك بعد ذلك زيادة الجرعة إلى الجرعة المعتادة من 80 ملجم -100 ملجم يومياً. الجرعة اليومية القصوى التي سيصفها طبيبك هي 100 ملجم.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكبد، فقد يصف لك الطبيب جرعة أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا قمت بتناول أكثر مما ينبغي من ستراتيرا</strong>، قم فورا باستشارة الطبيب أو توجه إلى قسم الإصابات بأقرب مستشفى. ويجب عليك أن تخبرهم بعدد الكبسولات التي قمت بتناولها. وتتضمن الأعراض الأكثر شيوعا التي قد تشكو منها<strong> </strong>عند تناول أكثر مما ينبغي من ستراتيرا: الأعراض الجانبية على الجهاز الهضمي و الميل للنعاس والغثيان و الرعشة و بعض السلوكيات الغريبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تناول ستراتيرا</strong></p><p dir="RTL">قم بتناول الجرعة في أقرب فرصة وقتما تتذكرها. لا تتناول أكثر من الجرعة اليومية المعتادة في الأربع و العشرين ساعة. ولا تتناول جرعة مزدوجة لتعويض ما فاتك من جرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول ستراتيرا</strong></p><p dir="RTL">لا توجد أية أعراض جانبية للتوقف عن تناول ستراتيرا في المعتاد، غير أن أعراض اضطراب تشتت الانتباه وفرط الحركة قد تظهر مجددا. ينبغي عليك أن تتناقش مع طبيبك أولاً قبل أن تتوقف عن تناول الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما سيفعله طبيبك&nbsp; عندما تكون تحت العلاج</strong></p><p dir="RTL"><strong>سيقوم طبيبك ببعض الاختبارات</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل البدء - للتأكد من أن ستراتيرا آمن وسوف يكون ذا فائدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد أن تبدأ - وسوف يتم ذلك على الأقل كل 6 أشهر، ولكن ربما أكثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وسوف يتم ذلك أيضا عندما يتم تغيير الجرعة. وستشمل هذه الاختبارات ما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قياس الطول والوزن لدى الأطفال والمراهقين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قياس ضغط الدم ومعدل ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التحقق مما إذا كان لديك أي مشاكل أو إذا كانت الآثار الجانبية قد صارت أسوأ أثناء أخذ ستراتيرا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العلاج على المدى الطويل</strong></p><p dir="RTL">ستراتيرا لا يحتاج أن يؤخذ إلى الأبد. إذا كنت تأخذ ستراتيرا لأكثر من عام، فإن طبيبك سيراجع العلاج الخاص بك، لمعرفة ما إذا كان لا يزال هناك حاجة إلى الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل الأدوية الأخرى، قد يتسبب ستراتيرا في حدوث بعض الآثار الجانبية، إلا أنها لا تظهر على جميع المرضى. على الرغم من أن بعض الأشخاص عانوا من آثار جانبية إلّا أن معظم الناس يجدون أن ستراتيرا يساعدهم. سيقوم طبيبك بالتحدث معك عن هذه الآثار الجانبية.</p><p dir="RTL">قد تكون بعض الآثار الجانبية خطيرة.<strong> </strong><strong>إذا كنت تعاني من أيٍّ من الآثار الجانبية أدناه قم بزيارة الطبيب على الفور.</strong></p><p dir="RTL"><strong>غير شائعة</strong> (يمكن أن تصيب من شخص واحد إلى 100 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور أو حدوث تسارع شديد في ضربات القلب، خفقان غير طبيعي في القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفكير أو الشعوربالرغبة في قتل نفسك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالعدوانية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بغير الودية والغضب (العدائية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلبات أو تغيرات المزاج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة، مع ضهور أعراض</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تورم الوجه والحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة بالتنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى (بقع على الجلد صغيرة وبارزة وبها حكة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض ذهانية بما في ذلك الهلوسة (سماع الأصوات أو رؤية الأشياء التي لا وجود لها)، واعتقاد أشياء ليست صحيحة أو مشبوهة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين الذين تقل أعمارهم عن 18 سنة لديهم خطر متزايد للإصابة بالآثار الجانبية مثل:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفكير أو الشعوربالرغبة في قتل نفسك (يمكن أن يصيب من شخص واحد إلى 100 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلبات أو تغيرات المزاج (يمكن أن تصيب من شخص واحد إلى 10 شخص)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لدى البالغين احتمال خطر منخفض (</strong>قد يصيب&nbsp; شخص واحد من أصل 1،000 شخص<strong>) من الآثار الجانبية مثل:</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>النوبات</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>أعراض ذهانية تشمل الهلوسة (سماع أصوات أو رؤية اأشياء غير موجودة) ، أو الاعتقاد بالأشياء غير صحيحة أو مشبوهة</strong><strong>.</strong></p><p dir="RTL"><strong>نادر</strong>ة )يمكن أن تصيب شخصا واحداً من أصل &nbsp;1000شخص (</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إصابة الكبد</strong></p><p dir="RTL"><strong>يجب عليك التوقف عن أخذ ستراتيرا و الاتصال بطبيبك على الفور إذا كنت تعاني من التالي:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بول داكن اللون</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو العينين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن الذي هو قرحة عند الضغط عليه (الرقة) على الجانب الأيمن&nbsp; تحت الأضلاع مباشرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتوعك (الغثيان) الغير مبرر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتعب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بأعراض تشبه الإنفلونزا</p><p dir="RTL"><strong>بعض</strong><strong> </strong><strong>الأعراض الأخرى تشمل التالي؛ يجب عليك إخبار طبيبك أو الصيدلي إذا اشتدّت</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>آثار جانبية شائعة جدّاً</strong><strong> </strong>(يمكن أن تصيب أكثر من شخص من أصل 10 أشخاص)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأطفال و المراهقين الذين تزيد أعمارهم عن ست سنوات</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>البالغون</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">- صداع</p><p dir="RTL">- ألم بالمعدة</p><p dir="RTL">- فقدان الشهية (عدم الشعور بالجوع)</p><p dir="RTL">&nbsp;-الشعور بالتوعك أو الإصابة بالمرض</p><p dir="RTL">- الشعور بالنعاس</p><p dir="RTL">-ارتفاع ضغط الدم</p><p dir="RTL">- ارتفاع ضربات القلب (النبض)</p><p dir="RTL">قد تختفي هذه الأعراض مع مرور الوقت لدى معظم المرضى.</p><p dir="RTL"><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p dir="RTL">- الشعور بالتوعك</p><p dir="RTL">&nbsp;-جفاف الفم</p><p dir="RTL">- صداع الراس</p><p dir="RTL">- انخفاض الشهية (عدم الشعور بالجوع)</p><p dir="RTL">- مشاكل في النوم، والاستمرار في النوم والاستيقاظ مبكراً</p><p dir="RTL">- زيادة ضغط الدم</p><p dir="RTL">- زيادة معدل ضربات القلب (النبض)</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>آثار جانبية شائعة </strong>(يمكن أن تصيب شخصا من أصل 10 أشخاص)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأطفال و المراهقين الذين تزيد أعمارهم عن ست سنوات</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>البالغون</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;-تصبح مزعجا أو تشعر بالهيجان</p><p dir="RTL">&nbsp;-مشاكل النوم بما في ذلك الاستيقاظ في وقت مبكر</p><p dir="RTL">&nbsp;-الإكتئاب</p><p dir="RTL">&nbsp;-الشعور بالحزن أو اليأس</p><p dir="RTL">&nbsp;-الشعور بالقلق</p><p dir="RTL">&nbsp;- تشنجات</p><p dir="RTL">&nbsp;- اتساع بؤبؤ العين</p><p dir="RTL">&nbsp;-الدوخة</p><p dir="RTL">- الإمساك</p><p dir="RTL">- فقدان الشهية</p><p dir="RTL">- اضطراب في المعدة، وعسر الهضم</p><p dir="RTL">- تورم، حمى وحكة في الجلد</p><p dir="RTL">&nbsp;-طفح جلدي</p><p dir="RTL">&nbsp;-الشعور بالكسل (الخمول)</p><p dir="RTL">&nbsp;-ألم في الصدر</p><p dir="RTL">&nbsp;-التعب</p><p dir="RTL">&nbsp;-فقدان الوزن</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp; -الشعور بالهيجان</p><p dir="RTL">&nbsp; -انخفاض الاهتمام بالجنس</p><p dir="RTL">&nbsp; -اضطراب النوم</p><p dir="RTL">&nbsp; -الاكتئاب</p><p dir="RTL">&nbsp;-الشعور بالحزن أو اليأس</p><p dir="RTL">&nbsp;-الشعور بالقلق</p><p dir="RTL">&nbsp;-الدوخة</p><p dir="RTL">&nbsp;-طعم غير طبيعي أو تغيير في المذاق لن يختفي</p><p dir="RTL">&nbsp;-رعشه</p><p dir="RTL">&nbsp;-وخز أو تنمل في اليدين أو القدمين</p><p dir="RTL">&nbsp;-النعاس والشعور بالتعب</p><p dir="RTL">&nbsp;-الإمساك</p><p dir="RTL">&nbsp;-ألم بالبطن</p><p dir="RTL">&nbsp;-عسر الهضم</p><p dir="RTL">&nbsp;-ريح في البطن (انتفاخ البطن)</p><p dir="RTL">&nbsp;-المرض</p><p dir="RTL">&nbsp;-سخونة و احمرار</p><p dir="RTL">&nbsp;-الشعور بنبض قلب سريع جدًآ</p><p dir="RTL">&nbsp;-تورم، حمى وحكة في الجلد</p><p dir="RTL">&nbsp;-زيادة التعرق</p><p dir="RTL">&nbsp;-طفح جلدي</p><p dir="RTL">&nbsp;-مشاكل في التبول مثل عدم القدرة على التبول، التبول المتكرر أو المتردد، الألم لدى التبول.</p><p dir="RTL">&nbsp;-التهاب البروستاتا</p><p dir="RTL">&nbsp;-آلام في الفخذ عند الرجال</p><p dir="RTL">&nbsp;-عدم القدرة على الحصول على الانتصاب</p><p dir="RTL">&nbsp;- تأخر رعشة الجماع</p><p dir="RTL">&nbsp;-صعوبة الحفاظ على الانتصاب</p><p dir="RTL">&nbsp;-تشنجات الحيض</p><p dir="RTL">&nbsp;-نقص القوة أو الطاقة</p><p dir="RTL">&nbsp;-التعب</p><p dir="RTL">&nbsp;-الشعور بالكسل (الخمول)</p><p dir="RTL">&nbsp;-قشعريرة</p><p dir="RTL">&nbsp;-الشعور بالانفعال و التوتر الشّديد</p><p dir="RTL">&nbsp;-الشعور بالعطش</p><p dir="RTL">&nbsp;-فقدان الوزن</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>آثار جانبية غير</strong><strong> </strong><strong>شائعة </strong>(يمكن أن تصيب شخصا من أصل 100 شخص)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأطفال و المراهقين الذين تزيد أعمارهم عن ست سنوات</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>البالغون</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">- الإغماء</p><p dir="RTL">&nbsp;-رعشه</p><p dir="RTL">- صداع نصفي</p><p dir="RTL">- عدم وضوح الرؤية</p><p dir="RTL">- إحساس بالجلد غير طبيعي، مثل حرق، وخز ، حكة، أو تنمل</p><p dir="RTL">- تنمل أو تخدر في اليدين أو القدمين</p><p dir="RTL">- تشنج</p><p dir="RTL">- الشعور أو حدوث تسارع شديد في ضربات القلب&nbsp; (امتداد QT)</p><p dir="RTL">- ضيق في التنفس</p><p dir="RTL">- زيادة التعرق</p><p dir="RTL">- حكة في الجلد</p><p dir="RTL">- نقص القوة أو الطاقة</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;-الأرق</p><p dir="RTL">&nbsp;-التشنج</p><p dir="RTL">&nbsp;-الإغماء</p><p dir="RTL">&nbsp;-الصداع النصفي</p><p dir="RTL">&nbsp;-عدم وضوح الرؤية</p><p dir="RTL">&nbsp;-نبض قلب غير طبيعي (إطالة QT)</p><p dir="RTL">&nbsp;-الشعور بالبرودة في أصابع اليدين والقدمين</p><p dir="RTL">&nbsp;-ألم في الصدر</p><p dir="RTL">&nbsp;-ضيق في التنفس</p><p dir="RTL">&nbsp;- طفح جلبي مصحوب بحكة حمراء (شرى)</p><p dir="RTL">&nbsp;-تقلصات العضلات</p><p dir="RTL">&nbsp;-الرغبة الشديدة في التبول</p><p dir="RTL">- انعدام النشوة الجنسية أونشوة جنسية غير طبيعية</p><p dir="RTL">&nbsp;-عدم انتظام الدورة الشهرية</p><p dir="RTL">&nbsp;-فشل في القذف</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>آثار جانبية ناذرة </strong>(يمكن أن تصيب شخصا من أصل 1000 شخص)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الأطفال و المراهقين الذين تزيد أعمارهم عن ست سنوات</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>البالغون</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">- ضعف الدورة الدموية مما يجعل أصابع القدم والأصابع تتخدر و شاحبة (مرض رينود)</p><p dir="RTL">- مشاكل في الذهاب إلى دورة المياه مثل التبول المتكرر أو المتردد، ألم لدى التبول</p><p dir="RTL">- الانتصاب لفترات طويلة ومؤلمة</p><p dir="RTL">- آلام الفخذ لدى الذكور</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;-ضعف الدورة الدموية مما يجعل أصابع القدم والأصابع مخدّرة و شاحبة (مرض رينود)</p><p dir="RTL">&nbsp;-الانتصاب لفترات طويلة وبشكل مؤلم</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار على النمو</strong></p><p dir="RTL">بعض الأطفال يعانون من نقص في النمو (الوزن والطول) عندما يبدؤون بأخذ ستراتيرا. ومع ذلك، مع العلاج على المدى الطويل، يتعافى الأطفال للوصول إلى الوزن و الطول المناسبين لأعمارهم.</p><p dir="RTL">سوف یراقب طبیبك طول و وزن طفلك بمرور الوقت. إذا كان طفلك لا ينمو أو لا يكتسب الوزن كما هو متوقع، قد يغير طبيبك جرعة طفلك أو يقرر وقف ستراتيرا مؤقتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التبليغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا شعرت بأيّ تأثير جانبيّ، أعلم طبيبك أو الصيدلي. ينطبق هذا أيضًا على كل تأثير جانبي محتمل غير مذكور في هذه النشرة. يمكنك أيضًا التبليغ عن الآثار الجانبيّة مباشرة عبر نظام الإبلاغ الوطني المذكور في القسم 6. بالتبليغ عن الآثار الجانبيّة، تساهم في تزويد معلومات إضافية حول سلامة الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ينبغي حفظ الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على العبوة والشريط بعد عبارة EXP.. ويشير ذلك التاريخ إلى آخر يوم بالشهر المذكور.</p><p dir="RTL">تحفظ الكبسولات في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">يجب عدم التخلص من الأدوية من خلال شبكة الصرف الصحي أو مع النفايات المنزلية. عليك الرجوع إلى الصيدلي لمعرفة كيفية التخلص من الأدوية الغير المستعملة. هذه التدابير تساعد في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات كبسولات ستراتيرا 10، 18، 25، 40 و</strong><strong> </strong><strong>60 ملجم</strong></p><p dir="RTL">- المادة الفعالة هي هيدروكلوريد الأتوموكزيتين. وتحتوي كل كبسولة على ما يعادل 10 ملجم و18 ملجم و25 ملجم و40 ملجم و60 ملجم من مادة أتوموكزيتين.</p><p dir="RTL">- تتضمن المحتويات الأخرى للكبسولة على مادة بريجيلاتينيزد النشاومادة دايميتيكون.</p><p dir="RTL">- يحتوي غلاف الكبسولات على لوريل سالفات الصوديوم و الجيلاتين. وتشمل ملونات غلاف الكبسولة:</p><p dir="RTL">أكسيد الحديد الأصفر E172 (18 ملجم و60 ملجم)</p><p dir="RTL">ثاني أكسيد التيتانيوم E171 (10 ملجم و18 ملجم و25 ملجم و40 ملجم و60 ملجم)</p><p dir="RTL">FD&amp;C الأزرق 2 &nbsp;)إنديجو كارمن(E132 (25 ملجم و40 ملجم و60 ملجم)</p><p dir="RTL">حبر أسود صالح للأكل (يحتوي على شيلاك وأكسيد الحديد الأسود E172)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل الدواء ومحتويات العبوة</strong></p><p dir="RTL">كبسولات صلبة 10 ملجم (كبسولات بيضاء مطبوع عليها ليلي 3227/10 ملجم، حوالي 15.5-16.1 مم طول)</p><p dir="RTL">كبسولات صلبة 18 ملجم (كبسولات بيضاء/ ذهبي مطبوع عليها ليلي 3238/18 ملجم، حوالي 15.5-16.1 مم طول)</p><p dir="RTL">كبسولات صلبة 25 ملجم (كبسولات بيضاء/زرقاء مطبوع عليها ليلي 3228/25 ملجم، حوالي 15.5-16.1 مم طول)</p><p dir="RTL">كبسولات صلبة 40 ملجم (كبسولات زرقاء مطبوع عليها ليلي 3229/40 ملجم، حوالي 15.5-16.1 مم طول)</p><p dir="RTL">كبسولات صلبة 60 ملجم (كبسولات زرقاء/ ذهبي مطبوع عليها ليلي 3239/60 ملجم، حوالي 17.5-18.1 مم طول)</p><p dir="RTL">تتوفر كبسولات ستراتيرا في علب من 7 ٬ 14 ٬ 28 و 56 كبسولة. قد لا تكون جميع الأحجام مسوقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong>حامل رخصة التسويق:</p><p dir="RTL">ليلي س.أ. جادة اندستريا 30، 28108 ألكوبنداس، مدريد، إسبانيا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المصنع:</p><p dir="RTL">ليلي دل كريبي،&nbsp; .Inc بويرتو ريكو، المنطقة الصناعية، 12.6 كلم&nbsp; 65<sup>th</sup>&nbsp; طريق إنفنتري.&nbsp; كرولينا، بويرتو ريكو .00985</p><p dir="RTL">&nbsp;</p><p dir="RTL">موقع التغليف الأوّلي و الثّانوي:</p><p dir="RTL">ليلي س.أ. جادة اندستريا 30، 28108 ألكوبنداس، مدريد، إسبانيا.</p><p dir="RTL">&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للحصول على معلومات عن هذا الدواء، يُرجى الاتصال بالشركة صاحبة تفويض التسويق المحلي</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شركة إيلاي ليلي آند كومباني &ndash; المملكة العربية السعودية</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ص.ب: 92120</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطابق 16، مبنى رقم 3074،</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; برج ب، أبراج العُليَّا</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شارع الأمير محمد بن عبد العزيز</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العُليَّا، الرياض</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">الخط المباشر:&nbsp; 966114617800+، 966 11 4617850+</p><p dir="RTL">الفاكس: 966112179900+</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                

STRATTERA 10 mg, 18 mg, 25 mg, 40 mg, 60 mg hard capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                

Each hard capsule contains atomoxetine hydrochloride equivalent to 10 mg, 18 mg, 25 mg, 40 mg, 60 mg of atomoxetine.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                

Capsule, hard
STRATTERA 10 mg capsules: hard capsule, opaque white, imprinted with “Lilly 3227” and “10 mg” in black ink, approximately 15.5-16.1 mm length
STRATTERA 18 mg capsules: hard capsule, gold (cap) and opaque white (body), imprinted with “Lilly 3238” and “18 mg” in black ink, approximately 15.5-16.1 mm length.
STRATTERA 25 mg capsules: hard capsule, opaque blue (cap) and opaque white (body), imprinted with “Lilly 3228” and “25 mg” in black ink, approximately 15.5-16.1 mm length.
STRATTERA 40 mg capsules: hard capsule, opaque blue, imprinted with “Lilly 3229” and “40 mg” in black ink, approximately 15.5-16.1 mm length.
STRATTERA 60 mg capsules: hard capsule, opaque blue (cap) and gold (body), imprinted with “Lilly 3239” and “60 mg” in black ink, approximately 17.5-18.1 mm length.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6&nbsp;years and older, in adolescents and in adults as<strong> </strong>part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.</p><p>In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Strattera should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. &nbsp;Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual&rsquo;s life.</p><p><u>Additional information for the safe use of this product:</u></p><p>A comprehensive treatment programme typically includes psychological, educational and social measures and is aimed at stabilising patients with a behavioural syndrome characterised by symptoms which may include chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and abnormal EEG. Learning may or may not be impaired.</p><p>Pharmacological treatment is not indicated in all patients with this syndrome and the decision to use the drug must be based on a very thorough assessment of the severity of the patient&rsquo;s symptoms and impairment in relation to the patient&rsquo;s age and the persistence of symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Strattera can be administered as a single daily dose in the morning. Patients who do not achieve a satisfactory clinical response (tolerability [e.g. nausea or somnolence] or efficacy) when taking Strattera as a single daily dose might benefit from taking it as twice daily evenly divided doses in the morning and late afternoon or early evening.</p><p>&nbsp;</p><p><em>Paediatric population:</em></p><p><u>Dosing of paediatric population up<strong> </strong>to 70&nbsp;kg Body Weight:</u></p><p>Strattera should be initiated at a total daily dose of approximately 0.5&nbsp;mg/kg. The initial dose should be maintained for a minimum of 7&nbsp;days prior to upward dose titration according to clinical response and tolerability. The recommended maintenance dose is approximately 1.2&nbsp;mg/kg/day (depending on the patient&rsquo;s weight and available dosage strengths of atomoxetine). No additional benefit has been demonstrated for doses higher than 1.2&nbsp;mg/kg/day. The safety of single doses over 1.8&nbsp;mg/kg/day and total daily doses above 1.8&nbsp;mg/kg have not been systematically evaluated. In some cases it might be appropriate to continue treatment into adulthood.</p><p>&nbsp;</p><p><u>Dosing of paediatric population over 70&nbsp;kg Body Weight:</u></p><p>Strattera should be initiated at a total daily dose of 40&nbsp;mg. The initial dose should be maintained for a minimum of 7&nbsp;days prior to upward dose titration according to clinical response and tolerability. The recommended maintenance dose is 80&nbsp;mg. No additional benefit has been demonstrated for doses higher than 80&nbsp;mg. The maximum recommended total daily dose is 100&nbsp;mg. The safety of single doses over 120&nbsp;mg and total daily doses above 150&nbsp;mg have not been systematically evaluated.</p><p>&nbsp;</p><p><em>Adults:</em></p><p>Strattera should be initiated at a total daily dose of 40&nbsp;mg. The initial dose should be maintained for a minimum of 7&nbsp;days prior to upward dose titration according to clinical response and tolerability. The recommended maintenance daily dose is 80&nbsp;mg to 100&nbsp;mg. The maximum recommended total daily dose is 100&nbsp;mg. The safety of single doses over 120&nbsp;mg and total daily doses above 150&nbsp;mg have not been systematically evaluated.</p><p>&nbsp;</p><p><u>Additional information for the safe use of this product:</u></p><p><em>Pre-treatment screening:</em></p><p>Prior to prescribing it is necessary to take an appropriate medical history and conduct a baseline evaluation of a patient&rsquo;s cardiovascular status, including blood pressure and heart rate (see sections 4.3 and 4.4).</p><p><strong>&nbsp;</strong></p><p><em>Ongoing monitoring:</em></p><p>Cardiovascular status should be regularly monitored with blood pressure and pulse recorded after each adjustment of dose and then at least every 6&nbsp;months. For paediatric patients the use of a centile chart is recommended. For adults, current reference guidelines for hypertension should be followed. (see section 4.4).</p><p>&nbsp;</p><p><em>Withdrawal of Treatment:</em></p><p>In the study programme no distinct withdrawal symptoms have been described. In cases of significant adverse effects, atomoxetine may be stopped abruptly; otherwise the drug may be tapered off over a suitable time period.</p><p>Treatment with Strattera need not be indefinite. Re-evaluation of the need for continued therapy beyond 1&nbsp;year should be performed, particularly when the patient has reached a stable and satisfactory response.</p><p>&nbsp;</p><p><u>Special Populations</u></p><p><em>Hepatic Insufficiency</em>: for patients with moderate hepatic insufficiency (Child-Pugh Class B), initial and target doses should be reduced to 50% of the usual dose. For patients with severe hepatic insufficiency (Child-Pugh Class C), initial dose and target doses should be reduced to 25% of usual dose. (see section 5.2)</p><p><em>Renal Insufficiency</em>: subjects with end stage renal disease had higher systemic exposure to atomoxetine than healthy subjects (about a 65&nbsp;% increase), but there was no difference when exposure was corrected for&nbsp;mg/kg dose. Strattera can therefore be administered to ADHD patients with end stage renal disease or lesser degrees of renal insufficiency using the usual dosing regimen. Atomoxetine may exacerbate hypertension in patients with end stage renal disease. (see section 5.2)</p><p>Approximately 7&nbsp;% of Caucasians have a genotype corresponding to a non-functional CYP2D6 enzyme (called CYP2D6 poor metabolisers). Patients with this genotype have a several fold<strong> </strong>higher exposure to atomoxetine when compared to patients with a functional enzyme. Poor metabolisers are therefore at higher risk of adverse events (see section<strong>s </strong>4.8 and 5.2). For patients with a known poor metaboliser genotype, a lower starting dose and slower up titration of the dose may be considered.</p><p><em>Elderly population:</em> the use of atomoxetine in patients over 65&nbsp;years of age has not been systematically evaluated.</p><p><em>Paediatric population under six&nbsp;years of age</em>: the safety and efficacy of Strattera in children under 6&nbsp;years of age have not been established. Therefore Strattera should not be used in children under 6&nbsp;years of age. (see section 4.4)</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For oral use. Strattera can be administered with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Atomoxetine should not be used in combination with monoamine oxidase inhibitors (MAOI). Atomoxetine should not be used within a minimum of 2 weeks after discontinuing therapy with MAOI. Treatment with MAOI should not be initiated within 2 weeks after discontinuing atomoxetine.

Atomoxetine should not be used in patients with narrow angle glaucoma, as in clinical trials the use of atomoxetine was associated with an increased incidence of mydriasis.

Atomoxetine should not be used in patients with severe cardiovascular or cerebrovascular disorders (see section 4.4 Special Warnings and Special Precautions for Use – Cardiovascular Effects)]. Severe cardiovascular disorders may include severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies (disorders caused by the dysfunction of ion channels). Severe cerebrovascular disorders may include cerebral aneurysm or stroke.

Atomoxetine should not be used in patients with pheochromocytoma or a history of pheochromocytoma (see section 4.4 Special Warnings and Special Precautions for Use – Cardiovascular Effects).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Suicide-related behaviour</u></p><p>Suicide related behaviour (suicide attempts and suicidal ideation) has been reported in patients treated with atomoxetine. In double blind clinical trials, suicide related behaviours were uncommon<strong> </strong>but more frequently observed among children and adolescents treated with atomoxetine compared to those treated with placebo, where there were no events. In adult double-blind clinical trials there was no difference in the frequency of suicide related behaviour between atomoxetine and placebo. Patients who are being treated for ADHD should be carefully monitored for the appearance or worsening of suicide related behaviour.</p><p>&nbsp;</p><p><u>Sudden death and pre-existing cardiac abnormalities</u></p><p>Sudden death has been reported in patients with structural cardiac abnormalities who were taking atomoxetine at usual doses. Although some serious structural cardiac abnormalities alone carry an increased risk of sudden death, atomoxetine should only be used with caution in patients with known serious structural cardiac abnormalities and in consultation with a cardiac specialist.</p><p>&nbsp;</p><p><u>Cardiovascular effects</u></p><p>Atomoxetine can affect heart rate and blood pressure.</p><p>Most patients taking atomoxetine experience a modest increase in heart rate (mean &lt;10 bpm) and/or increase in blood pressure (mean &lt;5 mm Hg) (see section 4.8).</p><p>However, combined data from controlled and uncontrolled ADHD clinical trials show that approximately 8-12% of children and adolescents, and 6-10% adults experience more pronounced changes in heart rate (20 beats per minute or greater) and blood pressure (15-20&nbsp;mmHg or greater). Analysis of these clinical trial data showed that approximately 15-26% of children and adolescents, and 27-32% of adults experiencing such changes in blood pressure and heart rate during atomoxetine treatment had sustained or progressive increases. Long-term sustained changes in blood pressure may potentially contribute to clinical consequences such as myocardial hypertrophy.</p><p>As a result of these findings, patients who are being considered for treatment with atomoxetine should have a careful history and physical exam to assess for the presence of cardiac disease, and should receive further specialist cardiac evaluation if initial findings suggest such history or disease.</p><p>It is recommended that heart rate and blood pressure be measured and recorded before treatment is started and, during treatment, after each adjustment of dose and then at least every 6&nbsp;months<strong> </strong>to detect possible clinically important increases. For paediatric patients the use of a centile chart is recommended. For adults, current reference guidelines for hypertension should be followed.</p><p>Atomoxetine should not be used in patients with severe cardiovascular or cerebrovascular disorders (see section 4.3 Contraindications &ndash; Severe Cardiovascular and Cerebrovascular Disorders). Atomoxetine should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure and heart rate, such as patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease.</p><p>Patients who develop symptoms such as palpitations, exertional chest pain, unexplained syncope, dyspnoea or other symptoms suggestive of cardiac disease during atomoxetine treatment should undergo a prompt specialist cardiac evaluation.</p><p>In addition, atomoxetine should be used with caution in patients with congenital or acquired long QT or a family history of QT prolongation (see sections 4.5 and 4.8).</p><p>As orthostatic hypotension has also been reported, atomoxetine should be used with caution in any condition that may predispose patients to hypotension or conditions associated with abrupt heart rate or blood pressure changes.</p><p><strong>&nbsp;</strong></p><p><u>Cerebrovascular effects</u></p><p>Patients with additional risk factors for cerebrovascular conditions (such as a history of cardiovascular disease, concomitant medications that elevate blood pressure) should be assessed at every visit for neurological signs and symptoms after initiating treatment with atomoxetine.</p><p>&nbsp;</p><p><u>Hepatic effects</u></p><p>Very rarely, spontaneous reports of liver injury, manifested by elevated hepatic enzymes and bilirubin with jaundice, have been reported. Also very rarely, severe liver injury, including acute liver failure, have been reported. Strattera should be discontinued in patients with jaundice or laboratory evidence of liver injury, and should not be restarted.</p><p>&nbsp;</p><p><u>Psychotic or manic symptoms</u></p><p>Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, mania or agitation in patients without a prior history of psychotic illness or mania can be caused by atomoxetine at usual doses. If such symptoms occur, consideration should be given to a possible causal role of atomoxetine, and discontinuation of treatment should be considered. The possibility that Strattera will cause the exacerbation of pre-existing psychotic or manic symptoms cannot be excluded.</p><p>&nbsp;</p><p><u>Aggressive behaviour, hostility or emotional lability</u></p><p>Hostility (predominantly aggression, oppositional behaviour and anger) was more frequently observed in clinical trials among children, adolescents and adults treated with Strattera compared to those treated with placebo. Emotional lability was more frequently observed in clinical trials among children treated with Strattera compared to those treated with placebo. Patients should be closely monitored for the appearance or worsening of aggressive behaviour, hostility or emotional lability.</p><p>&nbsp;</p><p><u>Possible allergic events</u></p><p>Although uncommon, allergic reactions, including anaphylactic reactions, rash, angioneurotic oedema, and urticaria, have been reported in patients taking atomoxetine.</p><p>&nbsp;</p><p><u>Seizures</u></p><p>Seizures are a potential risk with atomoxetine. Atomoxetine should be introduced with caution in patients with a history of seizure. Discontinuation of atomoxetine should be considered in any patient developing a seizure or if there is an increase in seizure frequency where no other cause is identified.</p><p>&nbsp;</p><p><u>Growth and development</u></p><p>Growth and development should be monitored in children and adolescents during treatment with atomoxetine<strong>. </strong>Patients requiring long‑term therapy should be monitored and consideration should be given to dose reduction or<strong><em> </em></strong>interrupting therapy in children and adolescents who are not growing or gaining weight satisfactorily.</p><p>Clinical data do not suggest a deleterious effect of atomoxetine on cognition or sexual maturation, however the amount of available long-term data is limited. Therefore, patients requiring long-term therapy should be carefully monitored.</p><p>&nbsp;</p><p><u>New-onset or worsening of Comorbid Depression, Anxiety and Tics</u></p><p>In a controlled study of paediatric patients with ADHD and co morbid chronic motor tics or Tourette&rsquo;s Disorder, atomoxetine-treated patients did not experience worsening of tics compared to placebo-treated patients. In a controlled study of adolescent patients with ADHD and co morbid Major Depressive Disorder, atomoxetine-treated patients did not experience worsening of depression compared to placebo-treated patients. In two controlled studies (one in paediatric patients and one in adult patients) of patients with ADHD and co-morbid anxiety disorders, atomoxetine-treated patients did not experience worsening of anxiety compared to placebo-treated patients.</p><p>There have been rare postmarketing reports of anxiety and depression or depressed mood and very rare reports of tics in patients taking atomoxetine (see section 4.8).</p><p>Patients who are being treated for ADHD with atomoxetine should be monitored for the appearance or worsening of anxiety symptoms, depressed mood and depression or tics.</p><p>&nbsp;</p><p><u>Paediatric population under six years of age</u></p><p>Strattera should not be used in patients less than six&nbsp;years of age as efficacy and safety have not been established in this age group.</p><p>&nbsp;</p><p><u>Other therapeutic use</u></p><p>Strattera is not indicated for the treatment of major depressive episodes and/or anxiety as the results of clinical trials in adults in these conditions, where ADHD is not present, did not show an effect compared to placebo (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Effects of other drugs on atomoxetine</em></p><p>&nbsp;</p><p><em>MAOIs </em></p><p>Atomoxetine should not be used with MAOIs (see section 4.3).</p><p><em>CYP2D6 inhibitors (SSRIs (e.g. fluoxetine, paroxetine), quinidine, terbinafine) </em></p><p>In patients receiving these drugs, atomoxetine exposure may be 6-to 8-fold increased and Css max 3 to 4 times higher, because it is metabolised by the CYP2D6 pathway. Slower titration and final lower dosage of atomoxetine may be necessary in patients who are already taking CYP2D6 inhibitor drugs. If a CYP2D6 inhibitor is prescribed or discontinued after titration to the appropriate atomoxetine dose has occurred, the clinical response and tolerability should be re-evaluated for that patient to determine if dose adjustment is needed.</p><p>Caution is advised when combining atomoxetine with potent inhibitors of cytochrome P450 enzymes other than CYP2D6 in patients who are poor CYP2D6 metabolisers as the risk of clinically relevant increases in atomoxetine exposure in vivo is unknown.</p><p>&nbsp;</p><p><em>Salbutamol (or other beta2 agonists)</em></p><p>Atomoxetine should be administered with caution to patients treated with high dose nebulised or systemically administered salbutamol (or other beta2 agonists) because cardiovascular effects can be potentiated.</p><p>Contradictory findings regarding this interaction were found. Systemically administered salbutamol (600&nbsp;&mu;g i.v. over 2&nbsp;hrs) in combination with atomoxetine (60&nbsp;mg twice daily for 5&nbsp;days) induced increases in heart rate and blood pressure. This effect was most marked after the initial coadministration of salbutamol and atomoxetine but returned towards baseline at the end of 8&nbsp;hours. However, in a separate study the effects on blood pressure and heart rate of a standard inhaled dose of salbutamol (200&nbsp;&mu;g) were not increased by the short term coadministration of atomoxetine (80&nbsp;mg once daily for 5&nbsp;days) in a study of healthy Asian adults who were extensive atomoxetine metabolisers. Similarly heart rate after multiple inhalations of salbutamol (800&nbsp;&mu;g) did not differ in the presence or absence of atomoxetine. Attention should be paid to monitoring heart rate and blood pressure, and dose adjustments may be justified for either atomoxetine or salbutamol (or other beta2 agonists) in the event of significant increases in heart rate and blood pressure during coadministration of these drugs.</p><p>There is the potential for an increased risk of QT interval prolongation when atomoxetine is administered with other QT prolonging drugs, (such as neuroleptics, class IA and III anti arrhythmics, moxifloxacin, erythromycin, methadone mefloquine, tricyclic antidepressants, lithium or cisapride) drugs that cause electrolyte imbalance (such as thiazide diuretics) and drugs that inhibit CYP2D6.</p><p>Seizures are a potential risk with atomoxetine. Caution is advised with concomitant use of medicinal drugs which are known to lower the seizure threshold (such as tricyclic antidepressants or SSRIs, neuroleptics, phenothiazines or butyrophenone, mefloquine, chloroquine, bupropion or tramadol). (see section 4.4). In addition, caution is advised when stopping concomitant treatment with benzodiazepines due to potential withdrawal seizures.</p><p>&nbsp;</p><p><em>Anti-hypertensive drugs</em></p><p>Atomoxetine should be used cautiously with antihypertensive drugs. Because of a possible increase in blood pressure, atomoxetine may decrease the effectiveness of antihypertensive drugs / drugs used to treat hypertension. Attention should be paid to monitoring of blood pressure and review of treatment of atomoxetine or antihypertensive drugs may be justified in the case of significant changes of blood pressure.</p><p>&nbsp;</p><p><em>Pressor agents or drugs that increase blood pressure</em></p><p>Because of possible increase in effects on blood pressure, atomoxetine should be used cautiously with pressor agents or medications that may increase blood pressure (such as salbutamol). Attention should be paid to monitoring of blood pressure, and review of treatment for either atomoxetine or pressor agents may be justified in the case of significant change in blood pressure.</p><p>&nbsp;</p><p><em>Drugs that Affect Noradrenaline</em></p><p>Drugs that affect noradrenaline should be used cautiously when co-administered with atomoxetine because of the potential for additive or synergistic pharmacological effects. Examples include antidepressants such as imipramine, venlafaxine and mirtazapine, or the decongestants pseudoephedrine or phenylephrine.</p><p>&nbsp;</p><p><em>Drugs that Affect Gastric pH</em></p><p>Drugs that elevate gastric pH (magnesium hydroxide/aluminium hydroxide, omeprazole) had no effect on atomoxetine bioavailability.</p><p>&nbsp;</p><p><em>Drugs Highly Bound to Plasma Protein</em></p><p>In vitro drug-displacement studies were conducted with atomoxetine and other highly bound drugs at therapeutic concentrations. Warfarin, acetylsalicylic acid, phenytoin, or diazepam did not affect the binding of atomoxetine to human albumin. Similarly, atomoxetine did not affect the binding of these compounds to human albumin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Animal studies in general do not indicate direct harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). For atomoxetine clinical data on exposed pregnancies are limited. Such data are insufficient to indicate either an association or a lack of association between atomoxetine and adverse pregnancy and/or lactation outcomes. Atomoxetine should not be used during pregnancy unless the potential benefit justifies the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Atomoxetine and/or its metabolites were excreted in the milk of rats. It is not known if atomoxetine is excreted in human milk. Because of the lack of data, atomoxetine should be avoided during breastfeeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Data on the effects on the ability to drive and use machines are limited. Strattera has a minor influence on the ability to drive and use machines. Atomoxetine has been associated with increased rates of fatigue, somnolence, and dizziness relative to placebo in paediatric and adult patients.<em> </em>Patients should be advised to use caution when driving a car or operating hazardous machinery until they are reasonably certain that their performance is not affected by atomoxetine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Paediatric population</u>:</p><p><em>&nbsp;</em></p><p><em><u>Summary of the safety profile</u></em></p><p>In paediatric placebo-controlled trials, headache, abdominal pain<sup>1</sup> and decreased appetite are the adverse events most commonly associated with atomoxetine, and are reported by about 19%, 18% and 16% of patients respectively, but seldom lead to drug discontinuation (discontinuation rates are 0.1% for headache, 0.2% for abdominal pain and 0.0% for decreased appetite). Abdominal pain and decreased appetite are usually transient.</p><p><s>&nbsp;</s></p><p>Associated with decreased appetite, some patients experienced growth retardation early in therapy in terms of both weight and height gain. On average,<em> </em>after an initial decrease in weight and height gain, patients treated with atomoxetine recovered to mean weight and height as predicted by group baseline data over the long-term treatment.</p><p>&nbsp;</p><p>Nausea, vomiting and somnolence<sup>2</sup> can occur in about 10% to 11% of patients particularly during the first&nbsp;month of therapy. However, these episodes were usually mild to moderate in severity and transient, and did not result in a significant number of discontinuation from therapy (discontinuation rates &pound; 0.5%).</p><p>&nbsp;</p><p>In both paediatric and adult placebo‑controlled trials, patients taking atomoxetine experienced increases in heart rate, systolic and diastolic blood pressure (see section 4.4).</p><p>&nbsp;</p><p>Because of its effect on noradrenergic tone, orthostatic hypotension (0.2%) and syncope (0.8%) have been reported in patients taking atomoxetine. Atomoxetine should be used with caution in any condition that may predispose patients to hypotension.</p><p>&nbsp;</p><p>The following table of undesirable effects is based on adverse event reporting and laboratory investigations from clinical trials and post marketing spontaneous reports in children and adolescents:</p><p>&nbsp;</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p>Frequency estimate: Very common (&sup3;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1,000 to &lt;1/100), rare (&sup3;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000).</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p>&sup3;1/10</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>&sup3;1/100 to &lt;1/10</p></td><td colspan="2" style="vertical-align:top"><p><strong>Uncommon</strong></p><p>&sup3;1/1,000 to &lt;1/100</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>&sup3;1/10,000 to &lt;1/1,000</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Appetite decreased.</p></td><td style="vertical-align:top"><p>Anorexia (loss of appetite).</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Irritability, mood swings, insomnia<sup>3</sup>, agitation<sup> </sup>*, anxiety, depression and depressed mood *, tics *.</p></td><td colspan="2" style="vertical-align:top"><p>Suicide-related events, aggression,</p><p>hostility,</p><p>emotional lability*, Psychosis (including hallucinations)*.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache, somnolence<sup>2</sup>.</p></td><td style="vertical-align:top"><p>Dizziness.</p></td><td colspan="2" style="vertical-align:top"><p>Syncope, tremor, migraine,</p><p>paraesthesia*,<sup> </sup>hypoaesthesia*, Seizure**.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Mydriasis.</p></td><td colspan="2" style="vertical-align:top"><p>Vision blurred.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Palpitations, sinus tachycardia.</p><p>QT interval prolongation<sup> </sup>**.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Raynaud&rsquo;s phenomenon.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea (See section 4.4)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastro intestinal disorders </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Abdominal pain<sup>1</sup>, vomiting, nausea.</p></td><td style="vertical-align:top"><p>Constipation, dyspepsia.</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepato-biliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Blood bilirubin increased*.</p></td><td style="vertical-align:top"><p>Abnormal/increased liver function tests, jaundice, hepatitis, liver injury, acute hepatic failure*.<sup> </sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dermatitis, pruritus, rash.</p></td><td colspan="2" style="vertical-align:top"><p>Hyperhidrosis,</p><p>allergic reactions.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary hesitation, urinary retention.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Priapism, male genital pain.</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue, lethargy.</p><p>chest pain (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Asthenia.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Blood pressure increased<sup>4</sup>,</p><p>heart rate increased<sup>4</sup>.</p></td><td style="vertical-align:top"><p>Weight decreased.</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><sup>1</sup>Also includes abdominal pain upper, stomach discomfort, abdominal discomfort and epigastric discomfort.</p><p><sup>2 </sup>Also includes sedation</p><p><sup>3 </sup>Includes initial, middle and terminal (early morning wakening) insomnia</p><p><sup>4 </sup>Heart rate and blood<sup> </sup>pressure findings are based on measured vital signs</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See section 4.4</p><p>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See section 4.4 and section 4.5</p><p>&nbsp;</p><p><u>CYP2D6 poor metabolisers (PM)</u></p><p>The following adverse events occurred in at least 2% of CYP2D6 poor metaboliser (PM) patients and were statistically significantly more frequent in PM&nbsp;patients compared with CYP2D6 extensive metaboliser (EM)&nbsp;patients: appetite decreased (24.1% of PMs, 17.0% of EMs); insomnia combined (including insomnia, middle insomnia and initial insomnia, 14.9% of PMs, 9.7% of EMs); depression combined (including depression, major depression, depressive symptom, depressed mood and dysphoria, 6.5% of PMs and 4.1% of EMs), weight decreased (7.3% of PMs, 4.4% of EMs), constipation 6.8% of PMs, 4.3% of EMs); tremor (4.5% of PMs, 0.9% of EMs); sedation (3.9% of PMs, 2.1% of EMs); excoriation (3.9% of PMs, 1.7% of EMs); enuresis (3.0% of PMs, 1.2% of EMs); conjunctivitis (2.5% of PMs, 1.2% of EMs); syncope (2.5% of PMs, 0.7% of EMs); early morning awakening (2.3% of PMs, 0.8% of EMs); mydriasis (2.0% of PMs, 0.6% of EMs). The following event did not meet the above criteria but is noteworthy: generalised anxiety disorder (0.8% of PMs and 0.1% of EMs). In addition, in trials lasting up to 10&nbsp;weeks, weight loss was more pronounced in PM&nbsp;patients (mean of 0.6&nbsp;kg in EM and 1.1kg in PM).</p><p>&nbsp;</p><p><u>Adults:</u></p><p><em><u>Summary of the safety profile</u></em></p><p>In adult ADHD clinical trials, the following system organ classes had the highest frequency of adverse events during treatment with atomoxetine: gastrointestinal, nervous system and psychiatric disorders. The most common adverse events (&ge;5%) reported were appetite decreased (14.9%), insomnia (11.3%) headache (16.3%), dry mouth (18.4%) and nausea (26.7%). The majority of these events were mild or moderate in severity and the events most frequently reported as severe were nausea, insomnia, fatigue and headache. A complaint of urinary retention or urinary hesitancy in adults should be considered potentially related to atomoxetine.</p><p>The following table of undesirable effects is based on adverse event reporting and laboratory investigations from clinical trials and post marketing spontaneous reports in adults.</p><p>&nbsp;</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p>Frequency estimate: Very common (&sup3;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1,000 to &lt;1/100), rare (&sup3;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p>&sup3;1/10</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>&sup3;1/100 to &lt;1/10</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>&sup3;1/1,000 to &lt;1/100</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>&sup3;1/10,000 to &lt;1/1,000</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Appetite decreased.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Insomnia<sup>2</sup>.</p></td><td style="vertical-align:top"><p>Agitation*, libido decreased, sleep disorder, depression and depressed mood*,<sup> </sup>anxiety,</p></td><td style="vertical-align:top"><p>Suicide-related events*, aggression, hostility and emotional lability*,<sup> </sup>restlessness, tics*.<sup> </sup></p></td><td style="vertical-align:top"><p>Psychosis (including hallucinations)<sup> </sup>*.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache.</p></td><td style="vertical-align:top"><p>Dizziness, dysgeusia, paraesthesia, somnolence (including sedation), tremor.</p></td><td style="vertical-align:top"><p>Syncope, migraine. hypoaesthesia<sup> </sup>*.</p></td><td style="vertical-align:top"><p>Seizure**.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vision blurred.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations, tachycardia.</p></td><td style="vertical-align:top"><p>QT interval prolongation**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Flushing, hot flush.</p></td><td style="vertical-align:top"><p>Peripheral coldness.</p></td><td style="vertical-align:top"><p>Raynaud&rsquo;s phenomenon.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea (see section 4.4).</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Dry mouth, nausea.</p></td><td style="vertical-align:top"><p>Abdominal pain<sup>1</sup>, constipation, dyspepsia, flatulence, vomiting.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepato-biliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abnormal/increased liver function tests, jaundice, hepatitis, liver injury, acute hepatic failure, blood bilirubin increased*.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dermatitis, hyperhydrosis, rash.</p></td><td style="vertical-align:top"><p>Allergic reactions<sup>4</sup>, pruritis, urticaria.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle spasms.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysuria, pollakuria, urinary hesitation, urinary retention.</p></td><td style="vertical-align:top"><p>Micturation urgency.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysmenorrhoea, ejaculation disorder, erectile dysfunction, prostatitis, male genital pain.</p></td><td style="vertical-align:top"><p>Ejaculation failure, menstruation irregular, orgasm abnormal.</p></td><td style="vertical-align:top"><p>Priapism.</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthenia, fatigue, lethargy, chills feeling jittery, irritability, thirst.</p></td><td style="vertical-align:top"><p>Feeling cold.</p><p>Chest pain (see section 4.4)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Blood pressure increased<sup>3</sup>,</p><p>heart rate increased<sup>3</sup>.</p></td><td style="vertical-align:top"><p>Weight decreased.</p></td><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>1</sup>Also includes abdominal pain upper, stomach discomfort, abdominal discomfort and epigastric discomfort.</p><p><sup>2 </sup>Also includes initial insomnia, middle insomnia and terminal (early morning wakening) insomnia.</p><p><sup>3 </sup>Heart rate and blood<sup> </sup>pressure findings are based on measured vital signs.</p><p><sup>4 </sup>Includes anaphylactic reactions and angioneurotic oedema.</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See section 4.4</p><p>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See section 4.4 and section 4.5</p><p>&nbsp;</p><p><u>CYP2D6 poor metabolisers (PM)</u></p><p>The following adverse events occurred in at least 2% of CYP2D6 poor metaboliser (PM) patients and were statistically significantly more frequent in PM&nbsp;patients compared with CYP2D6 extensive metaboliser (EM)&nbsp;patients: vision blurred (3.9% of PMs, 1.3% of EMs), dry mouth (34.5% of PMs, 17.4% of EMs), constipation (11.3% of PMs, 6.7% of EMs), feeling jittery (4.9% of PMs, 1.9% of EMs), decreased appetite (23.2% of PMs, 14.7% of EMs), tremor (5.4% of PMs, 1.2% of EMs), insomnia (19.2% of PMs, 11.3% of EMs), sleep disorder (6.9% of PMs, 3.4% of EMs), middle insomnia (5.4% of PMs, 2.7% of EMs), terminal insomnia (3% of PMs, 0.9% of EMs), urinary retention (5.9% of PMs, 1.2% of EMs), erectile dysfunction (20.9% of PMs, 8.9% of EMs), ejaculation disorder (6.1% of PMs, 2.2% of EMs), hyperhidrosis (14.8% of PMs, 6.8% of EMs), peripheral coldness (3% of PMs, 0.5% of EMs).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>The National Pharmacovigilance &nbsp;Center (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Signs and symptoms</u></p><p>During postmarketing, there have been reports of non-fatal acute and chronic overdoses of atomoxetine alone. The most commonly reported symptoms accompanying acute and chronic overdoses were gastrointestinal symptoms somnolence, dizziness, tremor and abnormal behaviour. Hyperactivity and agitation have also been reported. Signs and symptoms consistent with mild to moderate sympathetic nervous system activation (e.g. tachycardia, blood pressure increased, mydriasis, dry mouth) were also observed and reports of pruritus and rash have been received. Most events were mild to moderate. In some cases of overdose involving atomoxetine, seizures have been reported and very rarely QT prolongation. There have also been reports of fatal, acute overdoses involving a mixed ingestion of atomoxetine and at least one other drug.</p><p>There is limited clinical trial experience with atomoxetine overdose.</p><p>&nbsp;</p><p><u>Management</u></p><p>An airway should be established. Activated charcoal may be useful in limiting absorption if the patient presents within 1&nbsp;hour of ingestion.<em> </em>Monitoring of cardiac and vital signs is recommended, along with appropriate symptomatic and supportive measures. The patient should be observed for a minimum of 6&nbsp;hours. Because atomoxetine is highly protein-bound, dialysis is not likely to be useful in the treatment of overdose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Psychoanaleptics, centrally acting sympathomimetics</p><p>ATC code: N06BA09</p><p>&nbsp;</p><p><u>Mechanism of action and Pharmacodynamic effects</u></p><p>Atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters. Atomoxetine has minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors. Atomoxetine has two major oxidative metabolites: 4-hydroxyatomoxetine and N-desmethylatomoxetine. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the noradrenaline transporter but unlike atomoxetine, this metabolite also exerts some inhibitory activity at the serotonin transporter. However, any effect on this transporter is likely to be minimal as the majority of 4-hydroxyatomoxetine is further metabolised such that it circulates in plasma at much lower concentrations (1% of atomoxetine concentration in extensive metabolisers and 0.1% of atomoxetine concentration in poor metabolisers). N-Desmethylatomoxetine has substantially less pharmacological activity compared with atomoxetine. It circulates in plasma at lower concentrations in extensive metabolisers and at comparable concentrations to the parent drug in poor metabolisers at steady state.</p><p>Atomoxetine is not a psychostimulant and is not an amphetamine derivative. In a randomised, double-blind, placebo-controlled, abuse-potential study in adults comparing effects of atomoxetine and placebo, atomoxetine was not associated with a pattern of response that suggested stimulant or euphoriant properties.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>Paediatric population</u></p><p>Strattera has been studied in trials in over 5000 children and adolescents with ADHD. The acute efficacy of Strattera in the treatment of ADHD was initially established in six randomised, double-blind, placebo-controlled trials of six to nine&nbsp;weeks duration. Signs and symptoms of ADHD were evaluated by a comparison of mean change from baseline to endpoint for Strattera treated and placebo treated patients. In each of the six trials, atomoxetine was statistically significantly superior to placebo in reducing ADHD signs and symptoms.</p><p>Additionally, the efficacy of atomoxetine in maintaining symptom response was demonstrated in a 1&nbsp;year, placebo-controlled trial with over 400 children and adolescents, primarily conducted in Europe (approximately 3&nbsp;months of open label acute treatment followed by 9&nbsp;months of double-blind, placebo-controlled maintenance treatment). The proportion of patients relapsing after 1&nbsp;year was 18.7% and 31.4% (atomoxetine and placebo, respectively). After 1&nbsp;year of atomoxetine treatment, patients who continued atomoxetine for 6 additional&nbsp;months were less likely to relapse or to experience partial symptom return compared with patients who discontinued active treatment and switched to placebo (2% vs. 12% respectively). For children and adolescents periodic assessment of the value of ongoing treatment during long-term treatment should be performed.</p><p>Strattera was effective as a single daily dose and as a divided dose administered in the morning, and late afternoon/early evening. Strattera administered once daily demonstrated statistically significantly greater reduction in severity of ADHD symptoms compared with placebo as judged by teachers and parents.</p><p>&nbsp;</p><p><em>Active Comparator Studies</em></p><p>In a randomised, double-blind, parallel group, 6&nbsp;week paediatric study to test the non-inferiority of atomoxetine to a standard extended-release methylphenidate comparator, the comparator was shown to be associated with superior response rates compared to atomoxetine. The percentage of patients classified as responders was 23.5% (placebo), 44.6% (atomoxetine) and 56.4% (methylphenidate). Both atomoxetine and the comparator were statistically superior to placebo and methylphenidate was statistically superior to atomoxetine (p=0.016). However, this study excluded patients who were stimulant nonresponders.</p><p>&nbsp;</p><p><u>Adult population</u></p><p>Strattera has been studied in trials in over 4800 adults who met DSM-IV diagnostic criteria for ADHD. The acute efficacy of Strattera in the treatment of adults was established in six randomised, double-blind, placebo-controlled trials of ten to sixteen&nbsp;weeks&rsquo; duration. Signs and symptoms of ADHD were evaluated by a comparison of mean change from baseline to endpoint for atomoxetine treated and placebo treated patients. In each of the six trials, atomoxetine was statistically significantly superior to placebo in reducing ADHD signs and symptoms (Table X).&nbsp; Atomoxetine-treated patients had statistically significantly greater improvements in clinical global impression of severity (CGI-S) at endpoint compared to placebo-treated patients in all of the 6 acute studies, and statistically significantly greater improvements in ADHD-related functioning in all 3 of the acute studies in which this was assessed (Table X). Long-term efficacy was confirmed in 2 six-month placebo controlled studies, but not demonstrated in a third (Table X).</p><p>&nbsp;</p><p><strong>Table&nbsp;X&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean Changes in Efficacy Measures for Placebo-Controlled Studies</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:625px"><tbody><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td colspan="7"><p><strong>Changes from Baseline in Patients with at Least One Postbaseline Value (LOCF)</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td colspan="2"><p><strong>CAARS-Inv:SV or AISRS</strong><sup>a</sup></p></td><td colspan="2"><p><strong>CGI-S</strong></p></td><td colspan="2"><p><strong>AAQoL</strong></p></td></tr><tr><td><p><strong>Study</strong></p></td><td><p><strong>Treatment</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>Mean Change </strong></p></td><td><p><strong>p-value </strong></p></td><td><p><strong>Mean Change</strong></p></td><td><p><strong>p-value </strong></p></td><td><p><strong>Mean Change </strong></p></td><td><p><strong>p-value </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Acute </strong><strong>Studies</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>LYAA</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>ATX</p><p>PBO</p></td><td style="vertical-align:top"><p>133</p><p>134</p></td><td style="vertical-align:top"><p>-9.5</p><p>-6.0</p></td><td style="vertical-align:top"><p>0.006</p></td><td style="vertical-align:top"><p>-0.8</p><p>-0.4</p></td><td style="vertical-align:top"><p>0.011</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>LYAO</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>ATX</p><p>PBO</p></td><td style="vertical-align:top"><p>124</p><p>124</p></td><td style="vertical-align:top"><p>-10.5</p><p>-6.7</p></td><td style="vertical-align:top"><p>0.002</p></td><td style="vertical-align:top"><p>-0.9</p><p>-0.5</p></td><td style="vertical-align:top"><p>0.002</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>LYBY</p></td><td style="vertical-align:top"><p>ATX</p><p>PBO</p></td><td style="vertical-align:top"><p>72</p><p>75</p></td><td style="vertical-align:top"><p>-13.6</p><p>-8.3</p></td><td style="vertical-align:top"><p>0.007</p></td><td style="vertical-align:top"><p>-1.0</p><p>-0.7</p></td><td style="vertical-align:top"><p>0.048</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>LYDQ</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>ATX</p><p>PBO</p></td><td style="vertical-align:top"><p>171</p><p>158</p></td><td style="vertical-align:top"><p>-8.7</p><p>-5.6</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>-0.8</p><p>-0.6</p></td><td style="vertical-align:top"><p>0.022</p></td><td style="vertical-align:top"><p>14.9</p><p>11.1</p></td><td style="vertical-align:top"><p>0.030</p></td></tr><tr><td style="vertical-align:top"><p>LYDZ</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>ATX</p><p>PBO</p></td><td style="vertical-align:top"><p>192</p><p>198</p></td><td style="vertical-align:top"><p>-10.7</p><p>-7.2</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>-1.1</p><p>-0.7</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>15.8</p><p>11.0</p></td><td style="vertical-align:top"><p>0.005</p></td></tr><tr><td style="vertical-align:top"><p>LYEE</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>ATX</p><p>PBO</p></td><td style="vertical-align:top"><p>191</p><p>195</p></td><td style="vertical-align:top"><p>-14.3</p><p>-8.8</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>-1.3</p><p>-0.8</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>12.83</p><p>8.20</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Long-Term </strong><strong>Studies</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>LYBV</p></td><td style="vertical-align:top"><p>ATX</p><p>PBO</p></td><td style="vertical-align:top"><p>185</p><p>109</p></td><td style="vertical-align:top"><p>-11.6</p><p>-11.5</p></td><td style="vertical-align:top"><p>0.412</p></td><td style="vertical-align:top"><p>-1.0</p><p>-0.9</p></td><td style="vertical-align:top"><p>0.173</p></td><td style="vertical-align:top"><p>13.90</p><p>11.18</p></td><td style="vertical-align:top"><p>0.045</p></td></tr><tr><td style="vertical-align:top"><p>LYCU</p></td><td style="vertical-align:top"><p>ATX</p><p>PBO</p></td><td style="vertical-align:top"><p>214</p><p>216</p></td><td style="vertical-align:top"><p>-13.2</p><p>-10.2</p></td><td style="vertical-align:top"><p>0.005</p></td><td style="vertical-align:top"><p>-1.2</p><p>-0.9</p></td><td style="vertical-align:top"><p>0.001</p></td><td style="vertical-align:top"><p>13.14</p><p>8.62</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>LYCW</p></td><td style="vertical-align:top"><p>ATX</p><p>PBO</p></td><td style="vertical-align:top"><p>113</p><p>120</p></td><td style="vertical-align:top"><p>-14.3</p><p>-8.3</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>-1.2</p><p>-0.7</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr></tbody></table><p>Abbreviations: AAQoL = Adult ADHD Quality of Life Total Score; AISRS = Adult ADHD Investigator Symptom Rating Scale Total Score; ATX = atomoxetine; CAARS‑Inv:SV&nbsp;= Conners Adult ADHD Rating Scale, Investigator Rated, screening version Total ADHD Symptom Score; CGI-S = Clinical Global Impression of Severity; LOCF&nbsp;=&nbsp;last observation carried forward; PBO = placebo.</p><p>a ADHD symptom scales; results shown for Study LYBY are for AISRS; results for all others are for CAARS-Inv:SV.</p><p>&nbsp;</p><p>In sensitivity analyses using a baseline-observation-carried-forward method for patients with no postbaseline measure (i.e. all patients treated), results were consistent with results shown in Table&nbsp;X.</p><p>In analyses of clinically meaningful response in all 6 acute and both successful long-term studies, using a variety of a priori and post hoc definitions, atomoxetine-treated patients consistently had statistically significantly higher rates of response than placebo-treated patients (Table Y).</p><p>&nbsp;</p><p><strong>Table&nbsp;Y&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number (n) and Percent of Patients Meeting Criteria for Response in Pooled Placebo-Controlled Studies</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:643px"><tbody><tr><td colspan="2" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="3"><p><strong>Response Defined by</strong></p><p><strong>Improvement of at least 1 point on CGI-S</strong></p></td><td colspan="3"><p><strong>Response Defined by</strong></p><p><strong>40% Improvement on CAARS-Inv:SVat Endpoint </strong></p></td></tr><tr><td><p><strong>Group</strong></p></td><td><p><strong>Treatment</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>n (%)</strong></p></td><td><p><strong>p-value</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>n (%)</strong></p></td><td><p><strong>p-value</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Pooled Acute </strong><strong>Studies<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>ATX</p><p>PBO</p></td><td style="vertical-align:top"><p>640</p><p>652</p></td><td style="vertical-align:top"><p>401 (62.7%)</p><p>283 (43.4%)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>841</p><p>851</p></td><td style="vertical-align:top"><p>347 (41.3%)</p><p>215 (25.3%)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Pooled Long-Term </strong><strong>Studies<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>ATX</p><p>PBO</p></td><td style="vertical-align:top"><p>758</p><p>611</p></td><td style="vertical-align:top"><p>482 (63.6%)</p><p>301 (49.3%)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>663</p><p>557</p></td><td style="vertical-align:top"><p>292 (44.0%)</p><p>175 (31.4%)</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr></tbody></table><p><strong><sup>a</sup></strong>Includes all studies in Table X except: Acute CGI-S response analysis excludes&nbsp;2 studies in patients with comorbid disorders (LYBY, LYDQ); Acute CAARS response analysis excludes 1 study in which the CAARS was not administered (LYBY).</p><p>&nbsp;</p><p>In two of the acute studies, patients with ADHD and comorbid alcoholism or social anxiety disorder were studied and in both studies ADHD symptoms were improved. In the study with comorbid alcohol abuse, there were no differences between atomoxetine and placebo with respect to alcohol use behaviours. In the study with co-morbid anxiety, the comorbid condition of anxiety did not deteriorate with atomoxetine treatment.</p><p>The efficacy of atomoxetine in maintaining symptom response was demonstrated in a study where after an initial active treatment period of 24&nbsp;weeks, patients who met criteria for clinically meaningful response (as defined by improvement on both CAARS-Inv:SV and CGI-S scores) were randomized to receive atomoxetine or placebo for an additional 6&nbsp;months of double-blind treatment. Higher proportions of atomoxetine-treated patients than placebo-treated patients met criteria for maintaining clinically meaningful response at the end of 6&nbsp;months (64.3&nbsp;% vs. 50.0&nbsp;%; p=0.001). Atomoxetine-treated patients demonstrated statistically significantly better maintenance of functioning than placebo-treated patients as shown by lesser mean change on the Adult ADHD Quality of Life (AAQoL) total score at the 3-month interval (p=0.003) and at the 6-month interval (p=0.002).</p><p>&nbsp;</p><p><em>QT/QTc study</em></p><p>A thorough QT/QTc study, conducted in healthy adult CYP2D6 poor metabolizer (PM) subjects dosed up to 60&nbsp;mg of atomoxetine BID, demonstrated that at maximum expected concentrations the effect of atomoxetine on QTc interval was not significantly different from placebo. There was a slight increase in QTc interval with increased atomoxetine concentration.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of atomoxetine in children and adolescents are similar to those in adults. The pharmacokinetics of atomoxetine have not been evaluated in children under 6&nbsp;years of age.</p><p>Pharmacokinetic studies have shown that atomoxetine capsules and oral solution are bioequivalent.</p><p>&nbsp;</p><p><u>Absorption:</u> Atomoxetine is rapidly and almost completely absorbed after oral administration, reaching mean maximal observed plasma concentration (Cmax) approximately 1 to 2&nbsp;hours after dosing. The absolute bioavailability of atomoxetine following oral administration ranged from 63% to 94% depending upon inter-individual differences in the modest first pass metabolism. Atomoxetine can be administered with or without food.</p><p>&nbsp;</p><p><u>Distribution:</u> Atomoxetine is widely distributed and is extensively (98%) bound to plasma proteins, primarily albumin.</p><p>&nbsp;</p><p><u>Biotransformation:</u> Atomoxetine undergoes biotransformation primarily through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway. Individuals with reduced activity of this pathway (poor metabolisers) represent about 7% of the Caucasian population and, have higher plasma concentrations of atomoxetine compared with people with normal activity (extensive metabolisers). For poor metabolisers, AUC of atomoxetine is approximately 10-fold greater and Css, max is about 5- fold greater than extensive metabolisers. The major oxidative metabolite formed is 4-hydroxyatomoxetine that is rapidly glucuronidated. 4-Hydroxyatomoxetine is equipotent to atomoxetine but circulates in plasma at much lower concentrations. Although 4-hydroxyatomoxetine is primarily formed by CYP2D6, in individuals that lack CYP2D6 activity, 4-hydroxyatomoxetine can be formed by several other cytochrome P450 enzymes, but at a slower rate. Atomoxetine does not inhibit or induce CYP2D6 at therapeutic doses.</p><p><em>Cytochrome P450 Enzymes</em>: Atomoxetine did not cause clinically significant inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.</p><p>&nbsp;</p><p><u>Elimination:</u> The mean elimination half-life of atomoxetine after oral administration is 3.6&nbsp;hours in extensive metabolisers and 21&nbsp;hours in poor metabolisers. Atomoxetine is excreted primarily as 4-hydroxyatomoxetine-<em>O</em>-glucuronide, mainly in the urine.</p><p>Linearity/non-linearity: pharmacokinetics of atomoxetine are linear over the range of doses studied in both extensive and poor metabolisers.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>Hepatic impairment results in a reduced atomoxetine clearance, increased atomoxetine exposure (AUC increased 2-fold in moderate impairment and 4-fold in severe impairment), and a prolonged half-life of parent drug compared to healthy controls with the same CYP2D6 extensive metaboliser genotype. In patients with moderate to severe hepatic impairment (Child Pugh Class B and C) initial and target doses should be adjusted (see section 4.2).</p><p>Atomoxetine mean plasma concentrations for end stage renal disease (ESRD) subjects were generally higher than the mean for healthy control subjects shown by Cmax&nbsp;(7%&nbsp;difference) and AUC0-&yen;&nbsp;(about 65% difference) increases. After adjustment for body weight, the differences between the two groups are minimized. Pharmacokinetics of atomoxetine and its metabolites in individuals with ESRD suggest that no dose adjustment would be necessary (see section 4.2)<strong>.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, or reproduction and development. Due to the dose limitation imposed by the clinical (or exaggerated pharmacological) response of the animals to the drug combined with metabolic differences among species, maximum tolerated doses in animals used in nonclinical studies produced atomoxetine exposures similar to or slightly above those that are achieved in CYP2D6 poor metabolizing patients at the maximum recommended daily dose.</p><p>&nbsp;</p><p>A study was conducted in young rats to evaluate the effects of atomoxetine on growth and neurobehavioral and sexual development. Slight delays in onset of vaginal patency (all doses) and preputial separation (&sup3;10&nbsp;mg/kg/day) and slight decreases in epididymal weight and sperm number (&sup3;10&nbsp;mg/kg/day) were seen; however, there were no effects on fertility or reproductive performance. The significance of these findings to humans is unknown.</p><p>&nbsp;</p><p>Pregnant rabbits were treated with up to 100&nbsp;mg/kg/day of atomoxetine by gavage throughout the period of organogenesis. At this dose, in 1 of 3 studies, decrease in live foetuses, increase in early resorption, slight increases in the incidences of atypical origin of carotid artery and absent subclavian artery were observed. These findings were observed at doses that caused slight maternal toxicity. The incidence of these findings is within historical control values. The no-effect dose for these findings was 30&nbsp;mg/kg/day. Exposure (AUC) to unbound atomoxetine in rabbits, at 100&nbsp;mg/kg/day was approximately 3.3 times (CYP2D6 extensive metabolisers) and 0.4 times (CYP2D6 poor metabolisers) those in humans at the maximum daily dose of 1.4&nbsp;mg/kg/day. The findings in one of three rabbit studies were equivocal and the relevance to man is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Starch, pregelatinised (Maize)</p><p>Dimeticone</p><p>&nbsp;</p><p><u>Capsule shell:</u></p><p>Sodium laurilsulfate</p><p>Gelatin</p><p>&nbsp;</p><p><u>Capsule Shell Cap colourants</u>:</p><p>10&nbsp;mg: Titanium dioxide E 171</p><p>18&nbsp;mg: Yellow iron oxide E172</p><p>25&nbsp;mg, 40&nbsp;mg, and 60&nbsp;mg: FD&amp;C Blue 2 (Indigo Carmine) E132 and Titanium dioxide E 171</p><p>80&nbsp;mg and 100&nbsp;mg: Yellow iron oxide E172, Red iron oxide E172, Titanium dioxide E171</p><p>&nbsp;</p><p><u>Capsule Shell Body colourants</u>:</p><p>60&nbsp;mg: Yellow iron oxide E172</p><p>10&nbsp;mg, 18&nbsp;mg, 25&nbsp;mg: Titanium dioxide E 171</p><p>40&nbsp;mg: FD&amp;C Blue 2 (Indigo Carmine) E132 and Titanium dioxide E 171</p><p>&nbsp;</p><p>Edible Black Ink SW-9008 (containing Shellac and Black Iron Oxide E172) or Edible Black Ink SW-9010(containing Shellac and Black Iron Oxide E172).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister packs are composed of cold-form aluminum foil (CFF) on one side and vinyl coated aluminum foil on the other side. Available in pack sizes of 7, 14, 28 and 56 capsules. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The capsules are not intended to be opened. Atomoxetine is an ocular irritant. In the event of capsules content coming in contact with the eye, the affected eye should be flushed immediately with water, and medical advice obtained. Hands and any potentially contaminated surfaces should be washed as soon as possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eli Lilly S.A Avda. De la Industria, 30. 28108 Alcobendas. Madrid. Spain.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07 May 2015
Version 3

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>